

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/000884 A1

(51) International Patent Classification⁷: **C07K 14/32, A61K 39/07, A61P 31/04, C07K 16/12**

(74) Agent: SIEGEL, Susan, Alpert; Klarquist, Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(21) International Application Number:
PCT/US2004/017736

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 4 June 2004 (04.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/476,598 5 June 2003 (05.06.2003) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (US).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SCHNEERSON, Rachel [US/US]; 10601 Weymouth Street, Bethesda, MD 20814 (US). LEPPLA, Stephen [US/US]; 9501 Starmont Road, Bethesda, MD 20817 (US). ROBBINS, John, B. [US/US]; 3901 Rosemary Street, Chevy Chase, MD 20815 (US). SHILOACH, Joseph [US/US]; 1717 Mark Lane, Rockville, MD 20852 (US). KUBLER-KIELB, Joanna [PL/US]; 212 Congressional Lane #201, Rockville, MD 20852 (US). LIU, Darrell [US/US]; 8907 Burdette Road, Bethesda, MD 20817 (US). MAJADLY, Fathy [US/US]; 5640 Wade Court, Apt. G, Frederic, MD 21703 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with a declaration as to non-prejudicial disclosures or exceptions to lack of novelty

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLY-GAMMA-GLUTAMIC CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED AGAINST BACILLI

(57) Abstract: Immunogenic compositions and methods for eliciting an immune response against *B. anthracis* and other bacilli are provided that include immunogenic conjugates of a poly- γ -glutamic acid (γ PGA) polypeptides of *B. anthracis*, or of another *Bacillus* that expresses a γ PGA polypeptide. The γ PGA conjugates elicit an effective immune response against *B. anthracis*, or against another *Bacillus*, in mammalian hosts to which the conjugates are administered. The preferred conjugate consists of γ -D-PGA and *Bacillus* protective antigen.



WO 2005/000884 A1

POLY-GAMMA-GLUTAMIC ACID CONJUGATES FOR ELICITING IMMUNE RESPONSES
DIRECTED AGAINST BACILLI

5

PRIORITY CLAIM

This application claims the benefit of U.S. Provisional Patent Application No. 60/476,59 filed June 5, 2003, which is incorporated herein by reference in its entirety.

FIELD OF THE DISCLOSURE

10

This invention relates to the field of immunology and, more specifically, to immunogenic compositions and methods for eliciting an effective immune response against *Bacillus anthracis* (*anthracis*).

BACKGROUND

15

Anthrax is an acute infectious disease caused by the bacterium *B. anthracis*. Anthrax commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, other herbivores), but it can also occur in humans, for example, when they are exposed to infected animals or tissue from infected animals, or anthrax spores.

20

The virulence of *B. anthracis* is dependent on Anthrax Toxin (AT), and the poly- γ -D-glutamic acid capsule (γ DPGA). The genes for the toxin, and the capsule, are carried by plasmids designated pX01 and pX02, respectively (Mikesell *et al.*, *Infect. Immun.* 39:371-76, 1983; Vodkin *et al.*, *Cell* 34:693-97, 1983; Green *et al.*, *Infect. Immun.* 49:291-97, 1985). AT is composed of three entities: Protective Antigen (PA) (the binding subunit of AT), and two enzymes known as Lethal Factor (LF) and Edema Factor (EF) (Mikesell *et al.*, *Infect. Immun.* 39:371-76, 1983; Vodkin *et al.* *Cell* 34:693-97, 1983). PA is an 83 kDa protein that is the main protective constituent of anthrax vaccines.

25

PA is necessary for vaccine immunogenicity (Ivins *et al.*, *Infect. Immun.* 60:662-68, 1992; Welkos and Friedlander, *Microb. Pathog.* 5:127, 1998). Antibodies against PA prevent anthrax from binding to host cells, thus abrogating toxicity (Little and Ivins, *Microbes. Infect.* 1:131-39, 1999). Additionally, antibodies to PA can inhibit the germination of spores while improving their phagocytosis and killing by macrophages (Welkos *et al.*, *Microbiology* 147:1677-85, 2001). Unfortunately, the currently licensed human anthrax vaccine (AVA, BioPort Corporation, Lansing MI) requires six vaccinations over eighteen months followed by yearly boosters to induce and maintain protective anti-PA titers (Pittman *et al.*, *Vaccine* 20:1412-20, 2002; Pittman *et al.*, *Vaccine* 20:972-78, 2001). In some vaccines, this regimen is associated with undesirable local reactogenic (Pittman *et al.*, *Vaccine* 20:972-78, 2001).

35

Thus, while certain prophylactic and treatment schemes may prove useful in preventing o

directed toward anthrax. In particular, there is a need for an effective and safe vaccine that would require fewer doses to confer immunity to anthrax.

BRIEF SUMMARY OF SPECIFIC EMBODIMENTS

5 An immunogenic conjugate is disclosed herein. The immunogenic conjugate includes a *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide covalently linked to a carrier, wherein the conjugate elicits an immune response in a subject. A composition including the immunogenic conjugate and a pharmaceutically acceptable carrier is also disclosed herein.

10 A method of eliciting an immune response against a *Bacillus* antigenic epitope in a subject is also disclosed. The method includes introducing into the subject a composition including the immunogenic conjugate and a pharmaceutically acceptable carrier, thereby eliciting an immune response in the subject. Optionally, the composition includes an adjuvant.

Further disclosed herein are isolated antibodies that bind to the *Bacillus* γ PGA polypeptide. In one embodiment, the isolated antibodies recognize antigenic epitopes on both the *Bacillus* γ PGA polypeptide and the carrier protein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a GLC-MS spectrum analysis of the *rPA*-Cys-Gly₃- γ DPGA₁₀-C conjugate, demonstrating that L-Glu can be separated from D-Glu and measured in order to calculate the number of γ DPGA chains incorporated into the protein of the conjugate.

FIG. 2A-2D are a set of MALDI-TOF spectra, showing the mass spectra of recombinant *B. anthracis* *rPA* (FIG. 2A); Br-*rPA* (FIG. 2B); *rPA*-Cys-Gly₃- γ DPGA₁₀-C conjugate containing an average of 11 γ DPGA chains per *rPA* (FIG. 2C); and *rPA*-Cys-Gly₃- γ DPGA₁₀-C conjugate containing an average of 16 γ DPGA chains per *rPA* (FIG. 2D).

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:

SEQ ID NO: 1 is the amino acid sequence of human immunodeficiency virus (HIV)-1 Tat protein.

SEQ ID NOs: 2 and 3 show the nucleic and amino acid sequences of *B. anthracis* protective antigen.

DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

I. Abbreviations

5	ADH:	adipic acid dihydrazide
	AT:	anthrax toxin
	ATR:	anthrax toxin receptor
	EDAC:	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl
	EF:	edema factor
10	γPGA:	poly-γ-glutamic acid capsule from a <i>Bacillus</i>
	γDPGA:	poly-γ-D- glutamic acid capsule from <i>B. anthracis</i>
	γLPGA:	poly-γ-L- glutamic acid capsule from a <i>Bacillus</i>
	GLC-MS:	gas-liquid chromatography-mass spectrometry
	kDa:	kilodaltons
15	LC-MS:	liquid chromatography-mass spectrometry
	LeTx:	lethal toxin
	LF:	lethal factor
	LPS:	lipopolysaccharide
	MALDI-TOF:	matrix-assisted laser desorption ionization time-of-flight
20	μg:	microgram
	μl:	microliter
	PA:	protective antigen
	PBS:	phosphate buffered saline
	rEPA:	recombinant <i>Pseudomonas aeruginosa</i> exotoxin A
25	rPA:	recombinant <i>B. anthracis</i> protective antigen
	SBAP:	succinimidyl 3-(bromoacetamido) propionate
	SFB:	succinimidylformylbenzoate
	SPDP:	<i>N</i> -hydroxysuccinimide ester of 3-(2-pyridyl dithio)-propionic acid
30	SLV:	succinimidyllevulinate

II. Terms

Unless otherwise noted, technical terms are used according to conventional usage.

Definitions of common terms in molecular biology may be found in Benjamin Lewin, *Genes VII*, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); and other similar references.

As used herein, the singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Also, as used herein, the term "comprises" means "includes." Hence "comprising A or B" means including A, B, or A and B. It is further to be understood that all nucleotide sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their

entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:

5

Adjuvant: A substance that non-specifically enhances the immune response to an antigen. Development of vaccine adjuvants for use in humans is reviewed in Singh *et al.* (*Nat. Biotechnol.* 17:1075-1081, 1999), which discloses that, at the time of its publication, aluminum salts, such as aluminum hydroxide (Amphogel, Wyeth Laboratories, Madison, NJ), and the MF59 microemulsion are the only vaccine adjuvants approved for human use.

10

In one embodiment, an adjuvant includes a DNA motif that stimulates immune activation, for example the innate immune response or the adaptive immune response by T-cells, B-cells, monocytes, dendritic cells, and natural killer cells. Specific, non-limiting examples of a DNA motif that stimulates immune activation include CpG oligodeoxynucleotides, as described in U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199.

15

Analog, Derivative or Mimetic: An analog is a molecule that differs in chemical structure from a parent compound, for example a homolog (differing by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, a change in ionization. Structural analogs are often found using quantitative structure activity relationships (QSAR), with techniques such as those disclosed in Remington (*The Science and Practice of Pharmacology*, 19th Edition (1995), chapter 28). A derivative is a biologically active molecule derived from the base structure. A mimetic is a molecule that mimics the activity of another molecule, such as a biologically active molecule. Biologically active molecules can include chemical structures that mimic the biological activities of a compound.

20

Animal: Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects, for example, humans, non-human primates, dogs, cats, horses, and cows.

25

Antibody: A protein (or protein complex) that includes one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

30

The basic immunoglobulin (antibody) structural unit is generally a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" (about 50-70 kDa) chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms "variable light chain" (V_L) and "variable heavy chain" (V_H) refer, respectively, to these light and

35

heavy chains.

As used herein, the term "antibodies" includes intact immunoglobulins as well as a number of well-characterized fragments. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to target protein (or epitope within a protein or fusion protein) would also be specific binding agents for that protein (or epitope). These antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')₂, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab')₂, a dimer of two Fab' fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody, a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Methods of making these fragments are routine (see, for example, Harlow and Lane, *Using Antibodies: A Laboratory Manual*, CSHL, New York, 1999).

Antibodies for use in the methods and devices of this disclosure can be monoclonal or polyclonal. Merely by way of example, monoclonal antibodies can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (*Nature* 256:495-97, 1975) or derivative methods thereof. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, *Using Antibodies: A Laboratory Manual*, CSHL, New York, 1999.

Antigen: A compound, composition, or substance that may be specifically bound by the products of specific humoral or cellular immunity, such as an antibody molecule or T-cell receptor. In one embodiment, an antigen is a *Bacillus* antigen, such as γ PGA.

Bacillus: A genus of bacteria whose collective features include degradation of most substrates derived from plant and animal sources, including cellulose, starch, pectin, proteins, agar, hydrocarbons, and others; antibiotic production; nitrification; denitrification; nitrogen fixation; facultative lithotrophy; autotrophy; acidophily; alkaliphily; psychrophily, thermophily and parasitism. Spore formation, universally found in the genus, is thought to be a strategy for survival in the soil environment, wherein the bacteria predominate. Aerial distribution of dormant spores likely explains the occurrence of *Bacillus* species in most habitats examined.

There are more than 40 recognized species in the genus *Bacillus* (Bergey's Manual of Systematic Bacteriology Vol. 2 (1986)). These include, but are not limited to, *B. acidocaldarius*, *B. alkalophilus*, *B. alvei*, *B. anthracis*, *B. azotoformans*, *B. badius*, *B. brevis*, *B. cereus*, *B. circulans*, *B. coagulans*, *B. fastidiosus*, *B. firmus*, *B. globisporus*, *B. insolitus*, *B. larvae*, *B. laterosporus*, *B. lentimorbus*, *B. lentus*, *B. licheniformis*, *B. macerans*, *B. macquariensis*, *B. marinus*, *B. megaterium*, *B. mycoides*, *B. pantothenicus*, *B. pasteurii*, *B. polymyxa*, *B. popillia*, *B. pumilus*, *B. schlegelii*, *B.*

sphaericus, *B. stearothermophilus*, *B. subtilis*, and *B. thuringiensis*. In one specific, non-limiting example, a *Bacillus* is *Bacillus anthracis*, the agent that causes anthrax.

5 ***Bacillus Anthracis*:** The etiologic agent of anthrax, *Bacillus anthracis* is a large, gram-positive, nonmotile, spore-forming bacterial rod. The virulence of *B. anthracis* is dependent on AT, and the γ DPGA capsule. The genes for the toxin, and the capsule, are carried by plasmids, designated pX01 and pX02, respectively (Mikesell *et al.*, *Infect. Immun.* 39:371-76, 1983; Vodkin *et al.*, *Cell* 34:693-97, 1983; Green *et al.*, *Infect. Immun.* 49:291-97, 1985).

AT is composed of three entities: PA (the binding subunit of AT), and two enzymes known as LF and EF (Mikesell *et al.*, *Infect. Immun.* 39:371-76, 1983; Vodkin *et al.*, *Cell* 34:693-97, 1983).
10 PA is an 83 kDa protein that is the main protective constituent of anthrax vaccines. PA binds to the anthrax toxin receptor (ATR) on cells and is then proteolytically cleaved by the enzyme furin with release of a 20 kDa fragment (Bradley *et al.*, *Nature* 414:225-29, 2001; Klimpel *et al.*, *PNAS* 89:10277-81, 1992). The 63 kDa PA remnant (PA₆₃) features a second binding domain and binds to either EF, an 89 kDa protein, to form edema toxin, or LF, a 90 kDa protein, to form lethal toxin (LeTx) (Leppa *et al.*, *Salisbury Med. Bull. Suppl.* 68:41-43, 1990). The resulting complex is
15 internalized into the cell within endosomes (Singh *et al.*, *Infect. Immun.* 67:1853-59, 1999; Friedlander, *J. Biol. Chem.* 261:7123-26, 1986).

The γ DPGA capsule of *B. anthracis* serves as an essential virulence factor during anthrax infection, inhibiting host defense mechanisms through inhibition of phagocytosis of the vegetative
20 cells by macrophages. While other *Bacillus* produce γ PGA in a mixture of both D- and L-forms, only *B. anthracis* is known to synthesize it exclusively in a D-conformation (Kovács *et al.*, *J. Chem. Soc.* 4255-59, 1952). When injected, γ DPGA has been shown to be a poor immunogen (Eisner, *Schweiz. Z. Pathol. Bakteriologie* 22:129-44, 1959; Ostroff *et al.*, *Proc. Soc. Exp. Biol. Med.* 99:345-47, 1958). The capsule also shields the vegetative form of *B. anthracis* from agglutination by monoclonal
25 antibodies to its cell wall polysaccharide (Ezzell *et al.*, *J. Clin. Microbiol.* 28:223-31, 1990).

Carrier: An immunogenic macromolecule to which an antigenic but not highly immunogenic molecule, such as, for example, a homopolymer of γ PGA, can be bound. When bound to a carrier, the bound molecule becomes more immunogenic. Carriers are chosen to increase the immunogenicity of the bound molecule and/or to elicit antibodies against the carrier which are
30 diagnostically, analytically, and/or therapeutically beneficial. Covalent linking of a molecule to a carrier confers enhanced immunogenicity and T-cell dependence (Pozsgay *et al.*, *PNAS* 96:5194-97, 1999; Lee *et al.*, *J. Immunol.* 116:1711-18, 1976; Dintzis *et al.*, *PNAS* 73:3671-75, 1976). Useful carriers include polymeric carriers, which can be natural (for example, polysaccharides, polypeptides or proteins from bacteria or viruses), semi-synthetic or synthetic materials containing one or more
35 functional groups to which a reactant moiety can be attached.

Examples of bacterial products for use as carriers include bacterial toxins, such as *B. anthracis* PA (including fragments that contain at least one antigenic epitope and analogs or derivatives capable of eliciting an immune response), LF and LeTx, and other bacterial toxins and toxoids, such as tetanus toxin/toxoid, diphtheria toxin/toxoid, *P. aeruginosa* exotoxin/toxoid/

pertussis toxin/toxoid, and *C. perfringens* exotoxin/toxoid. Viral proteins, such as hepatitis B surface antigen and core antigen can also be used as carriers, as well as proteins from higher organisms such as keyhole limpet hemocyanin, horseshoe crab hemocyanin, edestin, mammalian serum albumins, and mammalian immunoglobulins. Additional bacterial products for use as carriers include bacterial wall proteins and other products (for example, streptococcal or staphylococcal cell walls and lipopolysaccharide (LPS)).

Covalent Bond: An interatomic bond between two atoms, characterized by the sharing of one or more pairs of electrons by the atoms. The terms "covalently bound" or "covalently linked" refer to making two separate molecules into one contiguous molecule. The terms include reference to joining a γ PGA polypeptide directly to a carrier molecule, and to joining a γ PGA polypeptide indirectly to a carrier molecule, with an intervening linker molecule.

Epitope: An antigenic determinant. These are particular chemical groups or contiguous or non-contiguous peptide sequences on a molecule that are antigenic, that is, that elicit a specific immune response. An antibody binds a particular antigenic epitope based on the three dimensional structure of the antibody and the matching (or cognate) epitope.

γ PGA: A homopolymer of glutamic acid residues linked by γ peptide bonds. The glutamic acid residues constituting the γ PGA homopolymer can be solely in the L-form (γ LPGA) or the D-form (γ DPGA). When the form of the glutamic acid residues constituting the γ PGA homopolymer can be either the L-form or the D-form, or when the two forms are mixed in a single molecule, the term γ PGA is used. The weakly immunogenic and antiphagocytic capsule found on many species of *Bacillus*, which disguises the bacilli from immune surveillance, consists of γ PGA.

γ PGA Conjugate: A naturally occurring γ PGA polypeptide produced by *B. anthracis* or another *Bacillus* species or strain covalently linked to a carrier, as well as conjugates of a carrier with a polypeptide fragment, synthetic polypeptide, or chemically modified derivative of a γ PGA polypeptide. In some embodiments, the γ PGA conjugate will comprise a conjugate of a carrier protein with a synthetic γ PGA polypeptide having a selected peptide length and corresponding to a portion of a γ PGA polypeptide from *B. anthracis* or another *Bacillus* species or strain that possesses a γ PGA capsule.

Homopolymer: This term refers to a polymer formed by the bonding together of multiple units of a single type of molecular species, such as a single monomer (for example, an amino acid).

Immune Response: A response of a cell of the immune system, such as a B-cell, T-cell, macrophage or polymorphonucleocyte, to a stimulus. An immune response can include any cell of the body involved in a host defense response for example, an epithelial cell that secretes interferon or a cytokine. An immune response includes, but is not limited to, an innate immune response or inflammation.

Immunogenic Conjugate or Composition: A term used herein to mean a composition useful for stimulating or eliciting a specific immune response (or immunogenic response) in a vertebrate. In some embodiments, the immunogenic response is protective or provides protective immunity, in that it enables the vertebrate animal to better resist infection or disease progression from

the organism against which the immunogenic composition is directed.

Without wishing to be bound by a specific theory, it is believed that an immunogenic response can arise from the generation of an antibody specific to one or more of the epitopes provided in the immunogenic composition. The response can include a T-helper or cytotoxic cell-based response to one or more of the epitopes provided in the immunogenic composition. All three of these responses may originate from naïve or memory cells. A response can also include production of cytokines. One specific example of a type of immunogenic composition is a vaccine.

Immunogen: A compound, composition, or substance which is capable, under appropriate conditions, of stimulating the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal.

Immunologically Effective Dose: An immunologically effective dose of the γ PGA conjugates of the disclosure is therapeutically effective and will prevent, treat, lessen, or attenuate the severity, extent or duration of a disease or condition, for example, infection by *B. anthracis*.

Inhibiting or Treating a Disease: Inhibiting the full development of a disease or condition, for example, in a subject who is at risk for a disease such as anthrax. "Treatment" refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. As used herein, the term "ameliorating," with reference to a disease, pathological condition or symptom, refers to any observable beneficial effect of the treatment. The beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, a reduction in the number of relapses of the disease, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease.

Isolated: An "isolated" microorganism (such as a virus, bacterium, fungus, or protozoan) has been substantially separated or purified away from microorganisms of different types, strains, or species. Microorganisms can be isolated by a variety of techniques, including serial dilution and culturing.

An "isolated" biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as other chromosomal and extra-chromosomal DNA and RNA, proteins, and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids or proteins, or fragments thereof.

Linker: A molecule that joins two other molecules, either covalently, or through ionic, van der Waals or hydrogen bonds.

Opsonin: A macromolecule that becomes attached to the surface of a microbe and can be recognized by surface receptors of neutrophils and macrophages and that increases the efficiency of phagocytosis of the microbe. Opsonins include IgG antibodies, which are recognized by the Fc γ

receptor on phagocytes, and fragments of complement proteins, which are recognized by CR1 (CD35) and by the leukocyte integrin Mac-1.

Opsonophagocytosis: The process of attaching opsonins to microbial surfaces to target the microbes for phagocytosis.

5 **PA-based Immunogen:** A term used herein to refer to all forms of PA which are useful in immunogenic compositions and/or methods of the disclosure, including unmodified native or recombinant *B. anthracis* PA, or a variant or fragment thereof. Variants and fragments of PA are effective to elicit an anti-PA immune response in a subject to whom they are administered.

10 **Pharmaceutically Acceptable Carriers:** The pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds or molecules, such as one or more SARS-CoV nucleic acid molecules, proteins or antibodies that bind these proteins, and additional pharmaceutical agents.

15 In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

20 **Polypeptide:** A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.

25 The term "residue" or "amino acid residue" includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide.

30 Conservative amino acid substitutions are those substitutions that, when made, least interfere with the properties of the original protein, that is, the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. Examples of conservative substitutions are shown below.

35

	Original Residue	Conservative Substitutions
5	Ala	Ser
	Arg	Lys
	Asn	Gln, His
	Asp	Glu
	Cys	Ser
10	Gln	Asn
	Glu	Asp
	His	Asn; Gln
	Ile	Leu, Val
	Leu	Ile; Val
15	Lys	Arg; Gln; Glu
	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr
	Thr	Ser
20	Trp	Tyr
	Tyr	Trp; Phe
	Val	Ile; Leu

Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, for example, seryl or threonyl, is substituted for (or by) a hydrophobic residue, for example, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, for example, lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, for example, glutamyl or aspartyl; or (d) a residue having a bulky side chain, for example, phenylalanine, is substituted for (or by) one not having a side chain, for example, glycine.

Protective Antigen (PA): One of the three components of the anthrax toxin. PA is a secreted nontoxic protein with a molecular weight of 83 kDa and is the major protective constituent of anthrax vaccines. PA binds to the ATR on cells and is then proteolytically cleaved by the enzyme furin with release of a 20 kDa fragment (Bradley *et al.*, *Nature* 414:225-29, 2001; Klimpel *et al.*, *PNAS* 89:10277-81, 1992). The 63 kDa PA remnant (PA₆₃) features a second binding domain and binds to either EF, an 89 kDa protein, to form edema toxin, or LF, a 90 kDa protein, to form lethal toxin (LeTx). The sequence of PA is known, for example, as encoded by bases 143779 to 146073 of GenBank Accession No. NC 007322 (plasmid pXO1; SEQ ID NOs: 2 and 3, nucleic and amino acid sequences, respectively).

Protein: A biological molecule, particularly a polypeptide, expressed by a gene and comprised of amino acids.

Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide, protein, γ PGA conjugate, or other active

compound is one that is isolated in whole or in part from naturally associated proteins and other contaminants, wherein the peptide, protein, γ PGA conjugate, or other active compound is purified to a measurable degree relative to its naturally occurring state, for example, relative to its purity within a cell extract. In certain embodiments, the term "substantially purified" refers to a peptide, protein, γ PGA conjugate, or other active compound that has been isolated from a cell, cell culture medium, or other crude preparation and subjected to fractionation to remove various components of the initial preparation, such as proteins, cellular debris, and other components. Such purified preparations can include materials in covalent association with the active agent, such as glycoside residues or materials admixed or conjugated with the active agent, which may be desired to yield a modified derivative or analog of the active agent or produce a combinatorial therapeutic formulation, conjugate, fusion protein or the like. The term purified thus includes such desired products as peptide and protein analogs or mimetics or other biologically active compounds wherein additional compounds or moieties are bound to the active agent in order to allow for the attachment of other compounds and/or provide for formulations useful in therapeutic treatment or diagnostic procedures. Generally, substantially purified peptides, proteins, γ PGA conjugates, or other active compounds for use within the disclosure comprise more than 80% of all macromolecular species present in a preparation prior to admixture or formulation of the peptide, protein, γ PGA conjugate or other active compound with a pharmaceutical carrier, excipient, buffer, absorption enhancing agent, stabilizer, preservative, adjuvant or other co-ingredient in a complete pharmaceutical formulation for therapeutic administration. More typically, the peptide, protein, γ PGA conjugate or other active compound is purified to represent greater than 90%, often greater than 95% of all macromolecular species present in a purified preparation prior to admixture with other formulation ingredients. In other cases, the purified preparation may be essentially homogeneous, wherein other macromolecular species are not detectable by conventional techniques.

Recombinant Nucleic Acid: A sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques such as those described in Sambrook *et al.* (ed.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid.

Specific Binding Agent: An agent that binds substantially only to a defined target. Thus a protein-specific binding agent binds substantially only the defined protein, or to a specific region within the protein. As used herein, a specific binding agent includes antibodies and other agents that bind substantially to a specified polypeptide. The antibodies may be monoclonal or polyclonal antibodies that are specific for the polypeptide, as well as immunologically effective portions ("fragments") thereof.

The determination that a particular agent binds substantially only to a specific polypeptide may readily be made by using or adapting routine procedures. One suitable *in vitro* assay makes use of the Western blotting procedure (described in many standard texts, including Harlow and Lane, *Using Antibodies: A Laboratory Manual*, CSHL, New York, 1999).

5 **Spore:** A small, usually single-celled reproductive body that is highly resistant to desiccation and heat and is capable of growing into a new organism, produced especially by certain bacteria, fungi, algae, and non-flowering plants. Spores have proven to be the most durable type of cell found in nature, and in their cryptobiotic state of dormancy, they can remain viable for extremely long periods of time, perhaps millions of years. Spores do not form normally during active growth
10 and cell division. Rather, their differentiation begins when a population of vegetative cells passes out of the exponential phase of growth, usually as a result of nutrient depletion. Typically, one spore is formed per vegetative cell. In some examples, the mature spore is liberated by lysis of the mother cell (sporangium) in which it was formed.

15 Mature spores have no detectable metabolism, a state that is described as cryptobiotic. They are highly resistant to environmental stresses such as high temperature (some spores can be boiled for several hours and retain their viability), irradiation, strong acids, disinfectants, and the like. Although cryptobiotic, they retain viability indefinitely such that under appropriate environmental conditions, they germinate into vegetative cells.

20 **Therapeutically Effective Amount:** A quantity of a specified agent sufficient to achieve a desired effect in a subject being treated with that agent. For example, this may be the amount of a γ DPGA conjugate useful in increasing resistance to, preventing, ameliorating, and/or treating infection and disease caused by *B. anthracis* infection in a subject. Ideally, a therapeutically effective amount of an agent is an amount sufficient to increase resistance to, prevent, ameliorate, and/or treat infection and disease caused by *B. anthracis* infection in a subject without causing a substantial
25 cytotoxic effect in the subject. The effective amount of an agent useful for increasing resistance to, preventing, ameliorating, and/or treating infection and disease caused by *B. anthracis* infection in a subject will be dependent on the subject being treated, the severity of the affliction, and the manner of administration of the therapeutic composition.

30 **Toxoid:** A nontoxic derivative of a bacterial exotoxin produced, for example, by formaldehyde or other chemical treatment. Toxoids are useful in the formulation of immunogenic compositions because they retain most of the antigenic properties of the toxins from which they were derived.

III. Description of Several Embodiments

35 A. *Bacillus* γ PGA Polypeptide – Carrier Conjugates

Bacillus capsular γ PGA polypeptide – carrier conjugates (γ PGA conjugates) are disclosed herein. The γ PGA conjugates elicit an immune response in a subject, and inhibit or treat infection and/or disease caused by *B. anthracis* or other bacilli.

The weakly immunogenic and antiphagocytic γ PGA capsule, which consists of glutamic

acid residues linked by γ peptide bonds, disguises the bacilli from immune surveillance. As disclosed herein, *Bacillus* capsular γ PGA polypeptides include, but are not limited to, *B. anthracis*, *B.*

licheniformis, *B. pumilus*, and *B. subtilis* γ PGA polypeptides. All *Bacillus* besides *B. anthracis* that are known to produce γ PGA make a mixture of both the D- and L-forms, whereas *B. anthracis* produces exclusively γ DPGA. In one embodiment, the γ PGA conjugates disclosed herein are γ LPGA conjugates. In another embodiment, the γ PGA conjugates are γ DPGA conjugates. In a specific, non-limiting example, the γ DPGA conjugate is a *B. anthracis* γ DPGA conjugate.

Bacillus capsular γ PGA polypeptides can be isolated by many methods well known in the art, such as salt fractionation, phenol extraction, precipitation with organic solvents (for example, hexadecyltrimethylammonium bromide (cetavlon) or ethanol), affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, high performance liquid chromatography, gel filtration, isoelectric focusing, and the like. In one specific, non-limiting example, *Bacillus* capsular γ PGA polypeptides are extracted from the culture supernatant of growing bacilli by cetavlon precipitation, acidification to pH 1.5, precipitation with ethanol, and passage through a 2.5 x 100 cm Sepharose CL-4B column in 0.2M NaCl. The compositions of extracted γ PGA polypeptides are determined by methods well known in the art, such as ^1H -nuclear magnetic resonance (NMR) spectroscopy and ^{13}C -NMR spectroscopy; while their enantiomeric confirmations can be determined by gas-liquid chromatography-mass spectrometry (GLC-MS).

Synthetic γ PGA polypeptides of varying lengths (for example, about 5, 10, 15, or 20 residues) having either the D- or L-configuration can be readily synthesized by automated solid phase procedures well known in the art. Suitable syntheses can be performed by utilizing "T-boc" or "F-moc" procedures. Techniques and procedures for solid phase synthesis are described in *Solid Phase Peptide Synthesis: A Practical Approach*, by E. Atherton and R. C. Sheppard, published by IRL, Oxford University Press, 1989. In specific, non-limiting examples, the synthetic γ PGA polypeptide includes about 1 to about 20 glutamic acid residues, such as about 10 to about 15 glutamic acid residues, or about 10 glutamic acid residues. The compositions and purity of synthetic γ PGA polypeptides can be determined by GLC-MS and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) spectrometry.

Carriers for linking to γ PGA polypeptides as disclosed herein are chosen to increase the immunogenicity of the γ PGA polypeptides and/or to elicit antibodies against the carrier which are diagnostically, analytically, and/or therapeutically beneficial. Covalent linking of γ PGA polypeptides to a carrier confers enhanced immunogenicity and T-cell dependence. Useful carriers include polymeric carriers, which can be natural, semi-synthetic or synthetic materials containing one or more functional groups, for example primary and/or secondary amino groups, azido groups, hydroxyl groups, or carboxyl groups, to which a reactant moiety can be attached. The carrier can be water soluble or insoluble, and in some embodiments is a protein or polypeptide. Carriers that fulfill these criteria are generally known in the art (see, for example, Fattom *et al.*, *Infect. Immun.* 58:2309-12, 1990; Devi *et al.*, *PNAS* 88:7175-79, 1991; Szu *et al.*, *Infect. Immun.* 59:4555-61, 1991; Szu *et al.*, *J. Exp. Med.* 166:1510-24, 1987; and Pavliakova *et al.*, *Infect. Immun.* 68:2161-66, 2000).

Specific, non-limiting examples of water soluble polypeptide carriers include, but are not limited to, natural, semi-synthetic or synthetic polypeptides or proteins from bacteria or viruses. In one embodiment, bacterial products for use as carriers include bacterial wall proteins and other products (for example, streptococcal or staphylococcal cell walls and LPS), and soluble antigens of bacteria. In another embodiment, bacterial products for use as carriers include bacterial toxins. Bacterial toxins include bacterial products that mediate toxic effects, inflammatory responses, stress, shock, chronic sequelae, or mortality in a susceptible host. Specific, non-limiting examples of bacterial toxins include, but are not limited to: *B. anthracis* PA (for example, as encoded by bases 143779 to 146073 of GenBank Accession No. NC 007322, herein incorporated by reference), including variants that share at least 90%, at least 95%, or at least 98% amino acid sequence homology to PA, fragments that contain at least one antigenic epitope, and analogs or derivatives capable of eliciting an immune response; *B. anthracis* LF (for example, as encoded by the complement of bases 149357 to 151786 of GenBank Accession No. NC 007322); bacterial toxins and toxoids, such as tetanus toxin/toxoid (for example, as described in U.S. Pat. Nos. 5,601,826 and 6,696,065); diphtheria toxin/toxoid (for example, as described in U.S. Pat. Nos. 4,709,017 and 6,696,065); *P. aeruginosa* exotoxin/toxoid/ (for example, as described in U.S. Pat. Nos. 4,428,931, 4,488,991 and 5,602,095); pertussis toxin/toxoid (for example, as described in U.S. Pat. Nos. 4,997,915, 6,399,076 and 6,696,065); and *C. perfringens* exotoxin/toxoid (for example, as described in U.S. Pat. Nos. 5,817,317 and 6,403,094). Viral proteins, such as hepatitis B surface antigen (for example, as described in U.S. Pat. Nos. 5,151,023 and 6,013,264) and core antigen (for example, as described in U.S. Pat. Nos. 4,547,367 and 4,547,368) can also be used as carriers, as well as proteins from higher organisms such as keyhole limpet hemocyanin, horseshoe crab hemocyanin, edestin, mammalian serum albumins, and mammalian immunoglobulins.

In addition to bacterial and viral products, polysaccharide carriers are also useful in preparing the γ PGA polypeptide conjugates as disclosed herein. Polysaccharide carriers include, but are not limited to, dextran, capsular polysaccharides from microorganisms such as the Vi capsular polysaccharide from *S. typhi* (see, for example, U.S. Pat. No. 5,204,098); *Pneumococcus* group 12 (12F and 12A) polysaccharides; *Haemophilus influenzae* type d polysaccharide; and certain plant, fruit, and synthetic oligo- or polysaccharides which are immunologically similar to capsular polysaccharides, such as pectin, D-galacturonan, oligogalacturonate, or polygalacturonate (for example, as described in U.S. Pat. No. 5,738,855).

Specific, non-limiting examples of water insoluble carriers useful in preparing the γ PGA polypeptide conjugates as disclosed herein include, but are not limited to, aminoalkyl agarose (for example, aminopropyl or aminoethyl SEPHAROSE; Pharmacia Inc., Piscataway, N.J.), aminopropyl glass, cross-linked dextran, and the like, to which a reactive moiety can be attached. Other carriers can be used, provided that a functional group is available for covalently attaching a reactive group.

Binding of γ PGA polypeptides to a carrier can be direct or via a linker element. Linkers can include amino acids, including amino acids capable of forming disulfide bonds, but can also include other molecules such as, for example, polysaccharides or fragments thereof. Linkers can be chosen

so as to elicit their own immunogenic effect which may be either the same, or different, than that elicited by the γ PGA polypeptides and/or carriers disclosed herein. For example, such linkers can be bacterial antigens which elicit the production of antibodies to an infectious bacteria. In such instances, for example, the linker can be a protein or protein fragment of an infectious bacterium.

5 The covalent linking of the γ PGA polypeptides disclosed herein to the carrier can be carried out in any manner well known to one of skill in the art. Conjugation methods applicable to the present disclosure include, by way of non-limiting example, reductive amination, diazo coupling, thioether bond, disulfide bond, amidation and thiocarbamoyl chemistries. In one embodiment, the γ PGA polypeptides and/or the carrier are "activated" prior to conjugation. Activation provides the
10 necessary chemical groups for the conjugation reaction to occur. In one specific, non-limiting example, the activation step includes derivatization with adipic acid dihydrazide. In another specific, non-limiting example, the activation step includes derivatization with the *N*-hydroxysuccinimide ester of 3-(2-pyridyl dithio)-propionic acid (SPDP). In yet another specific, non-limiting example, the activation step includes derivatization with succinimidyl 3-(bromoacetamido) propionate (SBAP).
15 Further, non-limiting examples of derivatizing agents include succinimidylformylbenzoate (SFB) and succinimidyllevulinate (SLV).

 Following conjugation of a γ PGA polypeptide to a carrier, the γ PGA polypeptide-carrier conjugate can be purified by a variety of techniques well known to one of skill in the art. One goal of the purification step is to remove the unbound γ PGA polypeptide from the γ PGA polypeptide-carrier
20 conjugate. One method for purification, involving ultrafiltration in the presence of ammonium sulfate, is described in U.S. Pat. No. 6,146,902. Alternatively, γ PGA polypeptide-carrier conjugates can be purified away from unreacted γ PGA polypeptide and carrier by any number of standard techniques including, for example, size exclusion chromatography, density gradient centrifugation, hydrophobic interaction chromatography, or ammonium sulfate fractionation. See, for example,
25 Anderson *et al.*, *J. Immunol.* 137:1181-86, 1986 and Jennings & Lugowski, *J. Immunol.* 127:1011-18, 1981. The compositions and purity of the conjugates can be determined by GLC-MS and MALDI-TOF spectrometry.

 For γ PGA conjugates comprising γ PGA polypeptides bound at one point to a carrier, complex structural characteristics determine optimal immunogenicity for synthetic conjugates (see,
30 for example, Kabat, *Prog. Immunol.* 5:67-85, 1983; Pozsgay *et al.*, *PNAS* 96:5194-97, 1999; Lee *et al.*, *J. Immunol.* 116:1711-18, 1976; and Dintzis *et al.*, *PNAS* 73:3671-75, 1976). γ PGA polypeptide lengths must be sufficient to occupy a cognate antibody combining site. In addition, the density of the γ PGA polypeptide on the carrier determines the ability of the γ PGA conjugate to form both aggregates with the surface Ig receptor, and to permit interaction of the carrier fragments with T-
35 cells. In various embodiments of the present disclosure, γ PGA conjugates having a density of γ PGA polypeptide chains to carrier molecule of between about 5:1 to about 32:1, such as about 8:1 to about 22:1, or about 10:1 to about 15:1, are useful within the immunogenic compositions and methods described herein.

B. Analogs, Derivatives and Mimetics

In additional aspects of the disclosure, a γ PGA conjugate, PA-based immunogen, carrier, or component of an immunogenic conjugate or composition of the disclosure, includes a peptide mimetic of a naturally occurring or synthetic agent, for example a γ PGA polypeptide derivative of *B. anthracis* or another *Bacillus* species or strain. Exemplary conjugates and compositions are provided which
5 comprise a peptide or non-peptide molecule that mimics the tertiary binding structure and activity of a selected native peptide or functional domain (for example, immunogenic region or epitope) of a γ PGA polypeptide, carrier, linker, PA-based immunogen or other component of an immunogenic conjugate or composition of the disclosure. These peptide mimetics include recombinantly or chemically modified
10 peptides, as well as non-peptide agents such as small molecule drug mimetics, as further described herein.

Certain peptidomimetic compounds are based upon the amino acid sequence of the proteins and peptides described herein for use within the disclosure, including sequences of bacterial toxins such as *B. anthracis* PA (for example, as encoded by bases 143779 to 146073 of GenBank Accession No. NC 007322) and LF (for example, as encoded by the complement of bases 149357 to 151786 of
15 GenBank Accession No. NC 007322). Typically, peptidomimetic compounds are synthetic compounds having a three-dimensional structure (of at least part of the mimetic compound) that mimics, for example, the primary, secondary, and/or tertiary structural, and/or electrochemical characteristics of a selected peptide or protein, or a structural domain, active site, or binding region (for example, a
20 homotypic or heterotypic binding site, catalytic active site or domain, receptor or ligand binding interface or domain) thereof. The peptide-mimetic structure or partial structure (also referred to as a peptidomimetic motif of a peptidomimetic compound) will often share a desired biological activity with a native peptide or protein, as discussed herein (for example, immunogenic activity, such as binding to an antibody or a MHC molecule to activate CD8⁺ and/or CD4⁺ T-cells). Typically, at least one subject
25 biological activity of the mimetic compound is not substantially reduced in comparison to, and is often the same as or greater than, the activity of the native peptide on which the mimetic was modeled.

A variety of techniques well known to one of skill in the art are available for constructing peptide and protein mimetics with the same, similar, increased, or reduced biological activity as the corresponding native peptide or protein. Often these analogs, variants, derivatives and mimetics will
30 exhibit one or more desired activities that are distinct or improved from the corresponding native peptide or protein, for example improved characteristics of solubility, stability, and/or susceptibility to hydrolysis or proteolysis (see, for example, Morgan & Gainor, *Ann. Rep. Med. Chem.* 24:243-52, 1989). In addition, peptidomimetic compounds of the disclosure can have other desired characteristics that enhance their therapeutic application, such as increased cell permeability, greater affinity and/or avidity
35 for a binding partner, and/or prolonged biological half-life. The peptidomimetics of the disclosure will sometimes have a backbone that is partially or completely non-peptide, but with side groups identical to the side groups of the amino acid residues that occur in the peptide or protein on which the peptidomimetic is modeled. Several types of chemical bonds, for example, ester, thioester, thioamide,

retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.

In one embodiment, peptides (including polypeptides) useful within the disclosure are modified to produce peptide mimetics by replacement of one or more naturally occurring side chains of the 20 genetically encoded amino acids (or D-amino acids) with other side chains, for example with groups such as alkyl, lower alkyl, cyclic 4-, 5-, 6-, to 7-membered alkyl, amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, carboxy and the lower ester derivatives thereof, and with 4-, 5-, 6-, to 7-membered heterocyclics. For example, proline analogs can be made in which the ring size of the proline residue is changed from a 5 membered ring to a 4, 6, or 7 membered ring. Cyclic groups can be saturated or unsaturated, and if unsaturated, can be aromatic or non-aromatic. Heterocyclic groups can contain one or more nitrogen, oxygen, and/or sulphur heteroatoms. Examples of such groups include furazanyl, furyl, imidazolidinyl, imidazolyl, imidazoliny, isothiazolyl, isoxazolyl, morpholinyl (for example, morpholino), oxazolyl, piperazinyl (for example, 1-piperazinyl), piperidyl (for example, 1-piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl (for example, 1-pyrrolidinyl), pyrrolinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, thiomorpholinyl (for example, thiomorpholino), and triazolyl groups. These heterocyclic groups can be substituted or unsubstituted. Where a group is substituted, the substituent can be alkyl, alkoxy, halogen, oxygen, or substituted or unsubstituted phenyl. Peptides and proteins, as well as peptide and protein analogs and mimetics, can also be covalently bound to one or more of a variety of nonproteinaceous polymers, for example, polyethylene glycol, polypropylene glycol, or polyoxyalkenes, as described in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; and 4,179,337.

Other peptide and protein analogs and mimetics within the scope of the disclosure include glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in amino acid side chains or at the N- or C-termini, by means which are well known in the art. These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues (for example, lysine or arginine). Acyl groups are selected from the group of alkyl-moieties including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species. Covalent attachment to carrier proteins, for example, immunogenic moieties, can also be employed.

In addition to these modifications, glycosylation alterations of biologically active peptides and proteins (including a γ PGA conjugate, PA-based immunogen, carrier, or component of an immunogenic conjugate or composition of the disclosure) can be made, for example, by modifying the glycosylation patterns of a peptide during its synthesis and processing, or in further processing steps. In one embodiment, this is accomplished by exposing the peptide to glycosylating enzymes derived from cells that normally provide such processing, for example, mammalian glycosylation enzymes. Deglycosylation enzymes can also be successfully employed to yield useful modified peptides and

proteins within the disclosure. Also embraced are versions of a native primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, for example, phosphotyrosine, phosphoserine, or phosphothreonine, or other moieties, including ribosyl groups or cross-linking reagents.

- 5 Peptidomimetics can also have amino acid residues that have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties, particularly those that have molecular shapes similar to phosphate groups. In some embodiments, the modifications will be useful labeling reagents, or serve as purification targets (for example, affinity ligands).

10 *C. Specific Binding Agents*

- The disclosure provides specific binding agents that bind a γ PGA polypeptide of *B. anthracis* or another *Bacillus* species or strain, or a γ PGA conjugate as disclosed herein. The binding agent can be used to purify and detect the γ PGA polypeptides, as well as for detection and diagnosis of *B. anthracis*. Examples of the binding agents are a polyclonal or monoclonal antibody (including
15 humanized monoclonal antibody), and fragments thereof, that bind to any of the γ PGA polypeptides or γ PGA conjugates disclosed herein.

- Monoclonal or polyclonal antibodies can be raised to recognize a γ PGA polypeptide and/or a γ PGA conjugate as described herein, or a analog or derivative thereof. Substantially pure γ PGA conjugate suitable for use as immunogen can be prepared as described above. Monoclonal or
20 polyclonal antibodies to the γ PGA conjugate can then be prepared.

- Monoclonal antibodies to the polypeptides can be prepared from murine hybridomas according to the classic method of Kohler & Milstein (*Nature*, 256:495-97, 1975), or a derivative method thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected immunogen (for example, a γ PGA conjugate) over a period of a few weeks. The mouse is then
25 sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the
30 supernatant fluid of the wells by immunoassay procedures, such as the enzyme-linked immunoabsorbent assay (ELISA), as originally described by Engvall (*Meth. Enzymol.*, 70:419-39, 1980), or a derivative method thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, *Using Antibodies: A Laboratory Manual*, CSHL, New
35 York, 1999. Polyclonal antiserum containing antibodies can be prepared by immunizing suitable animals with an immunogen comprising a γ PGA conjugate.

 Effective antibody production (whether monoclonal or polyclonal) is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary

in response to site of inoculations and dose, with either inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis *et al.* (*J. Clin. Endocrinol. Metab.*, 33:988-91, 1971).

- 5 Booster injections can be given at regular intervals, and antiserum harvested when the antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony *et al.*, *Handbook of Experimental Immunology*, Wier, D. (ed.), Chapter 19, Blackwell, 1973. A plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M).
- 10 Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (*Manual of Clinical Immunology*, Ch. 42, 1980).

- Antibodies of the present disclosure can be contained in blood plasma, serum, hybridoma supernatants and the like. Alternatively, the antibodies can be isolated to the extent desired by well known techniques in the art, such as, ion exchange chromatography, sizing chromatography, or
- 15 affinity chromatography. The antibodies can be purified so as to obtain specific classes or subclasses of antibody, such as IgM, IgG, IgA, IgG1, IgG2, IgG3, IgG4 and the like. Antibodies of the IgG class are of use for purposes of passive protection.

- Antibody fragments can be used in place of whole antibodies and can be readily expressed in prokaryotic host cells. Methods of making and using immunologically effective portions of
- 20 monoclonal antibodies, also referred to as "antibody fragments," are well known and include those described in Better & Horowitz, *Methods Enzymol.* 178:476-96, 1989; Glockshuber *et al.*, *Biochemistry* 29:1362-67, 1990; and U.S. Patent Nos. 5,648,237; 4,946,778; and 5,455,030. Conditions whereby a polypeptide/binding agent complex can form, as well as assays for the detection of the formation of a polypeptide/binding agent complex and quantitation of binding
- 25 affinities of the binding agent and polypeptide, are standard in the art. Such assays can include, but are not limited to, Western blotting, immunoprecipitation, immunofluorescence, immunocytochemistry, immunohistochemistry, fluorescence activated cell sorting, fluorescence *in situ* hybridization, immunomagnetic assays, ELISA, ELISPOT (Coligan *et al.*, *Current Protocols in Immunology*, Wiley, NY, 1995), agglutination assays, flocculation assays, cell panning, and the like,
- 30 as are well known to one of skill in the art.

- The antibodies or antibody fragments of the present disclosure have a number of diagnostic and therapeutic uses. For example, the antibodies or antibody fragments can be used for passive immunotherapy, such as by administering to a subject a therapeutically effective amount of the antibody or antibody fragments. In another example, the antibodies or antibody fragments can be
- 35 used as *in vitro* diagnostic agents in various immunoassays to test for the presence of *B. anthracis* or another *Bacillus* expressing a γ PGA polypeptide in biological (for example, clinical) samples, in meat and meat products, on surfaces such as food processing surfaces, or on surfaces of items subject to security testing (for example, baggage, freight, water treatment, postage handling, transportation facilities, and the like). Useful immunoassays include, but are not limited to, agglutination assays,

radioimmunoassays, ELISA, fluorescence assays, Western blots and the like. In one such assay, for example, the biological sample is contacted first with an antibody of the present disclosure which binds *Bacillus* γ PGA polypeptide, and then with a labeled second antibody to detect the presence of a *Bacillus*, such as *B. anthracis*, to which the first antibody has bound. Such assays can be, for example, of direct format (where a labeled first antibody is reactive with the γ PGA polypeptide), an indirect format (where a labeled second antibody is reactive with the first antibody), a competitive format (such as the addition of a labeled γ PGA polypeptide), or a sandwich format (where both labeled and unlabelled antibody are utilized), as well as other formats well known to one of skill in the art.

Binding agents of this disclosure can be bound to a substrate (for example, beads, tubes, slides, plates, nitrocellulose sheets, and the like) or conjugated with a detectable moiety, or both bound and conjugated. The detectable moieties contemplated for the present disclosure can include, but are not limited to, an immunofluorescent moiety (for example, fluorescein, rhodamine), a radioactive moiety (for example, ^{32}P , ^{125}I , ^{35}S), an enzyme moiety (for example, horseradish peroxidase, alkaline phosphatase), a colloidal gold moiety, and a biotin moiety. Such conjugation techniques are standard in the art (for example, see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, CSHL, New York, 1999; Yang et al., *Nature*, 382:319-24, 1996).

D. Pharmaceutical and Immunogenic Compositions and Uses Thereof

Pharmaceutical compositions (including therapeutic and prophylactic formulations) of a γ PGA conjugate and/or a PA-based immunogen are also encompassed by the present disclosure, and include a γ PGA conjugate and/or other biologically active agent as described herein, typically combined together with one or more pharmaceutically acceptable vehicles and, optionally, other therapeutic ingredients (for example, antibiotics, or anti-inflammatories).

Within the pharmaceutical compositions and methods of the disclosure, the γ PGA conjugate and/or other biologically active agent can be administered to subjects by a variety of mucosal administration modes, including by oral, rectal, intranasal, intrapulmonary, or transdermal delivery, or by topical delivery to other surfaces. Optionally, the γ PGA conjugate and/or other active agent can be administered by non-mucosal routes, including by intramuscular, subcutaneous, intravenous, intra-atrial, intra-articular, intraperitoneal, or parenteral routes. In other alternative embodiments, the γ PGA conjugate and/or other active agent can be administered *ex vivo* by direct exposure to cells, tissues or organs originating from a subject.

To formulate pharmaceutical compositions of the present disclosure, the γ PGA conjugate and/or other biologically active agent can be combined with various pharmaceutically acceptable additives, as well as a base or vehicle for dispersion of the γ PGA conjugate and/or other biologically active agent. Desired additives include, but are not limited to, pH control agents, such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, and the like. In addition, local anesthetics (for example, benzyl alcohol), isotonicizing agents (for example, sodium chloride, mannitol, sorbitol), adsorption inhibitors (for example, Tween 80), solubility enhancing agents (for example, cyclodextrins

and derivatives thereof), stabilizers (for example, serum albumin), and reducing agents (for example, glutathione) can be included. Adjuvants, such as aluminum hydroxide (for example, Amphogel, Wyeth Laboratories, Madison, NJ), Freund's adjuvant, MPL™ (3-O-deacylated monophosphoryl lipid A; Corixa, Hamilton IN) and IL-12 (Genetics Institute, Cambridge MA), among many other suitable
5 adjuvants well known in the art, can be included in the compositions. When the composition is a liquid, the tonicity of the formulation, as measured with reference to the tonicity of 0.9% (w/v) physiological saline solution taken as unity, is typically adjusted to a value at which no substantial, irreversible tissue damage will be induced at the site of administration. Generally, the tonicity of the solution is adjusted to a value of about 0.3 to about 3.0, such as about 0.5 to about 2.0, or about 0.8 to about 1.7.

10 The γ PGA conjugate and/or other biologically active agent can be dispersed in a base or vehicle, which can include a hydrophilic compound having a capacity to disperse the γ PGA conjugate and/or other biologically active agent, and any desired additives. The base can be selected from a wide range of suitable compounds, including but not limited to, copolymers of polycarboxylic acids or salts thereof, carboxylic anhydrides (for example, maleic anhydride) with other monomers (for example,
15 methyl (meth)acrylate, acrylic acid and the like), hydrophilic vinyl polymers, such as polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives, such as hydroxymethylcellulose, hydroxypropylcellulose and the like, and natural polymers, such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, and nontoxic metal salts thereof. Often, a biodegradable polymer is selected as a base or vehicle, for example, polylactic acid, poly(lactic acid-glycolic acid) copolymer,
20 polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer and mixtures thereof. Alternatively or additionally, synthetic fatty acid esters such as polyglycerin fatty acid esters, sucrose fatty acid esters and the like can be employed as vehicles. Hydrophilic polymers and other vehicles can be used alone or in combination, and enhanced structural integrity can be imparted to the vehicle by partial crystallization, ionic bonding, cross-linking and the like. The vehicle can be provided in a
25 variety of forms, including, fluid or viscous solutions, gels, pastes, powders, microspheres and films for direct application to a mucosal surface.

The γ PGA conjugate and/or other biologically active agent can be combined with the base or vehicle according to a variety of methods, and release of the γ PGA conjugate and/or other biologically active agent can be by diffusion, disintegration of the vehicle, or associated formation of water
30 channels. In some circumstances, the γ PGA conjugate and/or other biologically active agent is dispersed in microcapsules (microspheres) or nanocapsules (nanospheres) prepared from a suitable polymer, for example, isobutyl 2-cyanoacrylate (see, for example, Michael *et al.*, *J. Pharmacy Pharmacol.* 43:1-5, 1991), and dispersed in a biocompatible dispersing medium, which yields sustained delivery and biological activity over a protracted time.

35 The compositions of the disclosure can alternatively contain as pharmaceutically acceptable vehicles substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate. For solid compositions, conventional nontoxic pharmaceutically acceptable

vehicles can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

Pharmaceutical compositions for administering the γ PGA conjugate and/or other biologically active agent can also be formulated as a solution, microemulsion, or other ordered structure suitable for high concentration of active ingredients. The vehicle can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity for solutions can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of a desired particle size in the case of dispersible formulations, and by the use of surfactants. In many cases, it will be desirable to include isotonic agents, for example, sugars, polyalcohols, such as mannitol and sorbitol, or sodium chloride in the composition. Prolonged absorption of the γ PGA conjugate and/or other biologically active agent can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.

In certain embodiments, the γ PGA conjugate and/or other biologically active agent can be administered in a time release formulation, for example in a composition which includes a slow release polymer. These compositions can be prepared with vehicles that will protect against rapid release, for example a controlled release vehicle such as a polymer, microencapsulated delivery system or bioadhesive gel. Prolonged delivery in various compositions of the disclosure can be brought about by including in the composition agents that delay absorption, for example, aluminum monostearate hydrogels and gelatin. When controlled release formulations are desired, controlled release binders suitable for use in accordance with the disclosure include any biocompatible controlled release material which is inert to the active agent and which is capable of incorporating the γ PGA conjugate and/or other biologically active agent. Numerous such materials are known in the art. Useful controlled-release binders are materials that are metabolized slowly under physiological conditions following their delivery (for example, at a mucosal surface, or in the presence of bodily fluids). Appropriate binders include, but are not limited to, biocompatible polymers and copolymers well known in the art for use in sustained release formulations. Such biocompatible compounds are non-toxic and inert to surrounding tissues, and do not trigger significant adverse side effects, such as nasal irritation, immune response, inflammation, or the like. They are metabolized into metabolic products that are also biocompatible and easily eliminated from the body.

Exemplary polymeric materials for use in the present disclosure include, but are not limited to, polymeric matrices derived from copolymeric and homopolymeric polyesters having hydrolyzable ester linkages. A number of these are known in the art to be biodegradable and to lead to degradation products having no or low toxicity. Exemplary polymers include polyglycolic acids and polylactic acids, poly(DL-lactic acid-co-glycolic acid), poly(D-lactic acid-co-glycolic acid), and poly(L-lactic acid-co-glycolic acid). Other useful biodegradable or bioerodable polymers include, but are not limited to, such polymers as poly(epsilon-caprolactone), poly(epsilon-aprolactone-CO-lactic acid), poly(epsilon-aprolactone-CO-glycolic acid), poly(beta-hydroxy butyric acid), poly(alkyl-2-

cyanoacrilate), hydrogels, such as poly(hydroxyethyl methacrylate), polyamides, poly(amino acids) (for example, L-leucine, glutamic acid, L-aspartic acid and the like), poly(ester urea), poly(2-hydroxyethyl DL-aspartamide), polyacetal polymers, polyorthoesters, polycarbonate, polymaleamides, polysaccharides, and copolymers thereof. Many methods for preparing such formulations are well known to those skilled in the art (see, for example, *Sustained and Controlled Release Drug Delivery Systems*, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978). Other useful formulations include controlled-release microcapsules (U.S. Pat. Nos. 4,652,441 and 4,917,893), lactic acid-glycolic acid copolymers useful in making microcapsules and other formulations (U.S. Pat. Nos. 4,677,191 and 4,728,721) and sustained-release compositions for water-soluble peptides (U.S. Pat. No. 4,675,189).

10 The pharmaceutical compositions of the disclosure typically are sterile and stable under conditions of manufacture, storage and use. Sterile solutions can be prepared by incorporating the γ PGA conjugate and/or other biologically active agent in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the γ PGA conjugate and/or other biologically active agent into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated herein. In the case of sterile powders, methods of preparation include vacuum drying and freeze-drying which yields a powder of the γ PGA conjugate and/or other biologically active agent plus any additional desired ingredient from a previously sterile-filtered solution thereof. The prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

In accordance with the various treatment methods of the disclosure, the γ PGA conjugate and/or other biologically active agent can be delivered to a subject in a manner consistent with conventional methodologies associated with management of the disorder for which treatment or prevention is sought. In accordance with the disclosure herein, a prophylactically or therapeutically effective amount of the γ PGA conjugate and/or other biologically active agent is administered to a subject in need of such treatment for a time and under conditions sufficient to prevent, inhibit, and/or ameliorate a selected disease (for example, anthrax) or condition or one or more symptom(s) thereof.

Typical subjects intended for treatment with the compositions and methods of the present disclosure include humans, as well as non-human primates and other animals. To identify subjects for prophylaxis or treatment according to the methods of the disclosure, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition (for example, anthrax) as discussed herein, or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine environmental, familial, occupational, and other such risk factors that may be associated with the targeted or suspected disease or condition, as well as diagnostic methods, such as various ELISA and other immunoassay methods, which are available and well known in the art to detect and/or characterize disease-associated markers. These and other routine methods allow the clinician to select patients in need of therapy using the methods and pharmaceutical compositions of the disclosure. In accordance

with these methods and principles, a γ PGA conjugate and/or other biologically active agent can be administered according to the teachings herein as an independent prophylaxis or treatment program, or as a follow-up, adjunct or coordinate treatment regimen to other treatments, including surgery, vaccination, immunotherapy, hormone treatment, cell, tissue, or organ transplants, and the like.

5 The γ PGA conjugates can be used in coordinate vaccination protocols or combinatorial formulations with PA-based immunogens to enhance an immune response elicited by a PA-based immunogen alone. In exemplary embodiments, γ PGA-rPA induces both anti-PA and anti- γ PGA immune responses. In other embodiments, novel combinatorial immunogenic compositions and coordinate immunization protocols employ separate immunogens or formulations, each directed toward
10 eliciting an anti-PA or an anti- γ PGA immune response. Separate immunogens that elicit the anti-PA or anti- γ PGA immune response can be combined in a polyvalent immunogenic composition administered to a subject in a single immunization step, or they can be administered separately (in monovalent immunogenic compositions) in a coordinate immunization protocol. Typically, when the anti-PA and anti- γ PGA immunogens are administered separately, they are administered coordinately, in close
15 temporal sequence (for example, the anti-PA immunogen will be administered hours, one or two days, or within a week or two, prior to administration of the anti- γ PGA immunogen, or vice versa).

 The administration of the γ PGA conjugate and/or other biologically active agent of the disclosure can be for either prophylactic or therapeutic purpose. When provided prophylactically, the γ PGA conjugate and/or other biologically active agent is provided in advance of any symptom. The
20 prophylactic administration of the γ PGA conjugate and/or other biologically active agent serves to prevent or ameliorate any subsequent infection. When provided therapeutically, the γ PGA conjugate and/or other biologically active agent is provided at (or shortly after) the onset of a symptom of disease or infection. The γ PGA conjugate and/or other biologically active agent of the disclosure can thus be provided prior to the anticipated exposure to *B. anthracis* or another *Bacillus*, so as to attenuate the
25 anticipated severity, duration or extent of an infection and/or associated disease symptoms, after exposure or suspected exposure to the bacteria, or after the actual initiation of an infection.

 For prophylactic and therapeutic purposes, the γ PGA conjugate and/or other biologically active agent disclosed herein can be administered to the subject in a single bolus delivery, via continuous delivery (for example, continuous transdermal, mucosal or intravenous delivery) over an extended time
30 period, or in a repeated administration protocol (for example, by an hourly, daily or weekly, repeated administration protocol). The therapeutically effective dosage of the γ PGA conjugate and/or other biologically active agent can be provided as repeated doses within a prolonged prophylaxis or treatment regimen, that will yield clinically significant results to alleviate one or more symptoms or detectable conditions associated with a targeted disease or condition as set forth herein. Determination of effective
35 dosages in this context is typically based on animal model studies followed up by human clinical trials and is guided by administration protocols that significantly reduce the occurrence or severity of targeted disease symptoms or conditions in the subject. Suitable models in this regard include, for example, murine, rat, porcine, feline, non-human primate, and other accepted animal model subjects known in the art. Alternatively, effective dosages can be determined using *in vitro* models (for example,

immunologic and histopathologic assays). Using such models, only ordinary calculations and adjustments are required to determine an appropriate concentration and dose to administer a therapeutically effective amount of the γ PGA conjugate and/or other biologically active agent (for example, amounts that are effective to elicit a desired immune response or alleviate one or more symptoms of a targeted disease). In alternative embodiments, an effective amount or effective dose of the γ PGA conjugate and/or biologically active agent may simply inhibit or enhance one or more selected biological activities correlated with a disease or condition, as set forth herein, for either therapeutic or diagnostic purposes.

The actual dosage of the γ PGA conjugate and/or other biologically active agent will vary according to factors such as the disease indication and particular status of the subject (for example, the subject's age, size, fitness, extent of symptoms, susceptibility factors, and the like), time and route of administration, other drugs or treatments being administered concurrently, as well as the specific pharmacology of the γ PGA conjugate and/or other biologically active agent for eliciting the desired activity or biological response in the subject. Dosage regimens can be adjusted to provide an optimum prophylactic or therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental side effects of the γ PGA conjugate and/or other biologically active agent is outweighed in clinical terms by therapeutically beneficial effects. A non-limiting range for a therapeutically effective amount of a γ PGA conjugate and/or other biologically active agent within the methods and formulations of the disclosure is about 0.01 mg/kg body weight to about 10 mg/kg body weight, such as about 0.05 mg/kg to about 5 mg/kg body weight, or about 0.2 mg/kg to about 2 mg/kg body weight. The antibodies of the present disclosure will typically be administered in a dosage ranging from about 1 mg/kg body weight to about 10 mg/kg body weight of the subject, although a lower or higher dose can be administered.

Upon administration of a γ PGA conjugate (for example, γ PGA-PA) or related immunogenic composition of the disclosure (for example, via injection, aerosol, oral, topical or other route), the immune system of the subject typically responds to the immunogenic composition by producing antibodies specific for γ PGA and/or PA. Such a response signifies that an immunologically effective dose of the γ PGA conjugate or related immunogenic composition was delivered. An immunologically effective dosage can be achieved by single or multiple administrations (including, for example, multiple administrations per day), daily, or weekly administrations. For each particular subject, specific dosage regimens can be evaluated and adjusted over time according to the individual need and professional judgment of the person administering or supervising the administration of the γ PGA conjugate and/or other biologically active agent. In some embodiments, the antibody response of a subject administered the compositions of the disclosure will be determined in the context of evaluating effective dosages/immunization protocols. In most instances it will be sufficient to assess the antibody titer in serum or plasma obtained from the subject. Decisions as to whether to administer booster inoculations and/or to change the amount of the composition administered to the individual can be at least partially based on the antibody titer level. The antibody titer level can be based on, for example, an immunobinding assay which measures the concentration of antibodies in the serum which bind to a

specific antigen, for example, γ PGA and/or PA. The ability to neutralize *in vitro* and *in vivo* biological effects of the *B. anthracis* can also be assessed to determine the effectiveness of the treatment.

Dosage can be varied by the attending clinician to maintain a desired concentration at a target site (for example, the lungs or systemic circulation). Higher or lower concentrations can be selected
5 based on the mode of delivery, for example, trans-epidermal, rectal, oral, pulmonary, or intranasal delivery versus intravenous or subcutaneous delivery. Dosage can also be adjusted based on the release rate of the administered formulation, for example, of an intrapulmonary spray versus powder, sustained release oral versus injected particulate or transdermal delivery formulations, and so forth. To achieve the same serum concentration level, for example, slow-release particles with a release rate of 5
10 nanomolar (under standard conditions) would be administered at about twice the dosage of particles with a release rate of 10 nanomolar.

The methods of using γ PGA conjugates, and the related compositions and methods of the disclosure, are useful in increasing resistance to, preventing, ameliorating, and/or treating infection and disease caused by bacilli in animal hosts, and other, *in vitro* applications. In exemplary embodiments,
15 the methods and compositions are useful in increasing resistance to, preventing, ameliorating, and/or treating infection and disease caused by *B. anthracis* infection in animals and humans. These immunogenic compositions can be used for active immunization for prevention of *B. anthracis* infection, and for preparation of immune antibodies. In one embodiment, the immunogenic compositions and methods are designed to confer specific immunity against infection with *B. anthracis*,
20 and to induce antibodies specific to *B. anthracis* γ DPGA. The immunogenic compositions are composed of non-toxic components, suitable for infants, children of all ages, and adults.

The methods of the disclosure are broadly effective for treatment and prevention of bacterial disease and associated inflammatory, autoimmune, toxic (including shock), and chronic and/or lethal sequelae associated with bacterial infection. In selected embodiments, one or more symptoms or
25 associated effects of exposure to and/or infection with anthrax is/are prevented or treated by administration to a mammalian subject at risk of acquiring anthrax, or presenting with one or more anthrax symptom(s), of an effective amount of a γ PGA conjugate of the disclosure. Therapeutic compositions and methods of the disclosure for prevention or treatment of toxic or lethal effects of bacterial infection are applicable to a wide spectrum of infectious agents. Non-lethal toxicities that will
30 be ameliorated by these methods and compositions can include fatigue syndromes, inflammatory/autoimmune syndromes, hypoadrenal syndromes, weakness, cognitive symptoms and memory loss, mood symptoms, neurological and pain syndromes and endocrine symptoms. Any significant reduction or preventive effect of the γ PGA conjugate with respect to the foregoing disease condition(s) or symptom(s) administered constitutes a desirable, effective property of the subject
35 composition/method of the disclosure.

The compositions and methods of the disclosure are particularly useful for treatment and prevention of infection and toxic/morbidity effects of exposure to anthrax and/or other disease- or illness-causing bacilli. Additional embodiments of the disclosure are directed to diagnostic compositions and methods to identify individuals at risk for exposure, infection, toxic effects, or long

term deleterious effects of exposure to pathogenic bacteria, for example *B. anthracis*. In additional aspects of the disclosure, the methods and compositions disclosed herein are useful for identification of environmental agents, including *B. anthracis* and other bacilli expressing a γ PGA, including food-borne pathogenic bacilli. Certain individuals exposed to small amounts of bacterial products, such as those
5 derived from *B. anthracis*, presenting certain genetic or physiological backgrounds, are predisposed to development of chronic syndromes, including fatigue syndromes, inflammatory/autoimmune syndromes, hypoadrenal syndromes, weakness, cognitive symptoms and memory loss, mood symptoms, neurological and pain syndromes and endocrine symptoms. In this context, the methods and compositions of the disclosure are employed to detect, and alternatively to treat and/or ameliorate, such
10 ubiquitous environmental exposures and associated symptoms. For example, antibodies of the disclosure provide for screening for γ PGA in mammalian subjects or food products at risk of contact/infection with a *Bacillus* that expresses a γ PGA.

In related embodiments, the disclosure provides compositions, including but not limited to, mammalian serum, plasma, and immunoglobulin fractions, which contain antibodies that are
15 immunoreactive with a γ PGA of *B. anthracis* or another *Bacillus* species or strain. These antibodies and antibody compositions can be useful to prevent, treat, and/or ameliorate infection and disease caused by the microorganism. The disclosure also provides such antibodies in isolated form. In exemplary embodiments, high titer anti- γ PGA sera, antibodies isolated therefrom, or monoclonal antibodies, can be used for therapeutic treatment for patients with infection by *B. anthracis* or another
20 *Bacillus* species or strain. Antibodies elicited by the agents of this disclosure can be used for the treatment of established *B. anthracis* or other *Bacillus* infections, and can also be useful in providing passive protection to an individual exposed to *B. anthracis* or another *Bacillus*.

The instant disclosure also includes kits, packages and multi-container units containing the herein described pharmaceutical compositions, active ingredients, and/or means for administering the
25 same for use in the prevention and treatment of anthrax and other bacterial diseases and other conditions in mammalian subjects. Kits for diagnostic use are also provided. In one embodiment, these kits include a container or formulation that contains one or more of the γ PGA conjugates and/or other active agent described herein. In one example, this component is formulated in a pharmaceutical preparation for delivery to a subject. The γ PGA conjugate and/or other biologically
30 active agent is/are optionally contained in a bulk dispensing container or unit or multi-unit dosage form. Optional dispensing means can be provided, for example a pulmonary or intranasal spray applicator. Packaging materials optionally include a label or instruction indicating for what treatment purposes (for example, anthrax) and/or in what manner the pharmaceutical agent packaged therewith can be used.

35

The subject matter of the present disclosure is further illustrated by the following non-limiting Examples.

EXAMPLES

Example 1

Materials and Methods

Bacterial strains

- 5 *B. pumilus*, strain Sh18 (Goodman *et al.*, *Biochem.* 7:706-10, 1968), and *B. anthracis* strain A34, a pX01⁻, pX02⁺ variant derived from the Ames strain by repeated passage at 43°C, are described by Klein *et al.* (*Science* 138:1331-33, 1962).

Poly-γ-glutamic acid

- 10 γPGA was extracted from culture supernatants of *B. anthracis* or *B. pumilus* by acidification to pH 1.5, precipitation with ethanol, and passage through a 2 x 100 cm Sepharose CL-4B column in 0.2 M NaCl (Myerowitz *et al.*, *Infect. Immun.* 8:896-900, 1973). The composition of each γPGA was confirmed by ¹H-NMR and ¹³C-NMR and their enantiomeric compositions were determined by GLC-MS spectroscopy.

15

Analyses

- Amino acid analyses were conducted by GLC-MS after hydrolysis with 6 N HCl, 150°C, 1 hour, derivatization to heptafluorobutyl R-(-)-isobutyl esters and assayed with a Hewlett-Packard apparatus (Model HP 6890) with a HP-5 0.32 x 30 mm glass capillary column, temperature programming at 8°C/min, from 125°C to 250°C in the electron ionization (106 eV) mode (MacKenzie, *J. Assoc. Off. Anal. Chem.* 70:151-60, 1987). Under these conditions, D-glutamic acid is separated from the L-enantiomer so that the ratio of each can be calculated based on the ratio of D-glutamic acid relative to L-glutamic acid residues in the protein (FIG. 1). The number of peptide chains in L-peptide conjugates was calculated by the relative increase of total L-glutamic acid relative to aspartic acid.
- 20 Protein concentration was measured by the method of Lowry *et al.* (*J. Biol. Chem.* 193:266-73, 1951), free ε amino groups by Fields' assay (*Biochem. J.* 124:581-90, 1971), thiolation by release of 2-pyridylthio groups (*A*₃₄₃) (Carlsson *et al.*, *Biochem. J.* 173:723-37, 1978), and hydrazide as reported by Schneerson *et al.* (*J. Exp. Med.* 152:361-76, 1980). SDS-PAGE employed 14% gels according to the manufacturer's instructions. Double immunodiffusion was performed in 1.0% agarose gel in PBS.

30

MALDI-TOF

- Mass spectra were obtained with a PerSeptive BioSystems Voyager Elite DE-STR MALDI-TOF instrument (PE Biosystems, Framingham, MA) operated in the linear mode, 25 kV accelerating voltage and a 300 nanosecond ion extraction delay time. Samples for analysis were prepared by a
- 35 "sandwich" of matrix and analyte. First, 1 μl matrix (saturated solution of sinnapinic acid made in 1:1 CH₃CN and 0.1% trifluoroacetic acid) was dried on the sample stage. Second, 1 μl of sample and an additional 1 μl of matrix was applied. After the "sandwich" was dried, the sample was placed in the mass spectrometer.

Antigens

BSA (Sigma Chemical Co., St. Louis, MO) was dialyzed against pyrogen-free water, sterile-filtered, and freeze-dried. Recombinant Protective Antigen from *B. anthracis* and recombinant exotoxin A from *P. aeruginosa* were prepared and characterized as described by Ramirez *et al.* (*J. Ind. Microbiol. Biotechnol.* 28:232-38, 2002) and Johansson *et al.* (*J. Biotechnol.* 48:9-14, 1996). Exemplary synthetic polypeptides of γ PGA (AnaSpec, San Jose, CA) were synthesized by the method of Merrifield, with lengths of 5, 10, 15, or 20 residues. Their purity and authenticity were verified by GLC-MS, LC-MS and MALDI-TOF. γ PGA polypeptides were bound to carrier proteins at either the C- or the N-termini (-C indicates that the C-terminus is free; N- indicates that the amino-terminus is free). All reactions were conducted in a pH stat under argon.

- Type I:** NBrAc-Gly₃- γ DPGA_n-COOH(Br-Gly₃- γ DPGA_n-C)
NBrAc-Gly₃- γ LPGA_n-COOH(Br-Gly₃- γ LPGA_n-C)
- Type II:** NAc-L-Cys-Gly₃- γ DPGA_n-COOH(Cys-Gly₃- γ DPGA_n-C)
NAc-L-Cys-Gly₃- γ LPGA_n-COOH(Cys-Gly₃- γ LPGA_n-C)
- Type III:** NAc- γ DPGA_n-Gly₃-L-Cys-CONH₂(N- γ DPGA_n-Gly₃-Cys)
NAc- γ LPGA_n-Gly₃-L-Cys-CONH₂(N- γ LPGA_n-Gly₃-Cys)
- Type IV:** CHO-Gly₃- γ DPGA_n-COOH
- Type V:** NAc- γ DPGA_n-Gly₃-CO-AH
NAc- γ DPGA_n-CO-AH
- Type VI:** NAc- γ DPGA_n-Cys-CONH₂

Conjugation of BSA, rEPA and rPA with B. anthracis γ DPGA and B. pumilus γ DLPGA

BSA, rEPA and rPA were derivatized with adipic acid dihydrazide with modifications (Schnecrson *et al.*, *J. Exp. Med.* 152:361-76, 1980). The pH was maintained at 7.0 and 0.1 M EDAC used. The products, BSA-AH, rEPA-AH and rPA-AH, contained 2.0-4.8% hydrazide.

γ PGA was bound to rPA-AH or rEPA-AH with 0.01 M EDAC, the reaction mixture passed through a 1 x 90 cm Sephacryl S-1000 column in 0.2 M NaCl, and fractions reacting with anti-PA and anti- γ DPGA by an identity line were pooled.

Conjugation of Type I peptide with rPA via thioether bond

Step 1: Derivatization of BSA, rEPA and rPA with SPDP

To rPA (30 mg) in 1.5 ml of Buffer A' (PBS, 3% glycerol, 0.005 M EDTA, pH 7.6), SPDP (10 mg) in 50 μ l dimethyl sulfoxide (DMSO) was added in 10 μ l aliquots and reacted for 1 hour at pH 7.6.

The product, 2-pyridyldithio-propionyl-rPA (PDP-rPA) was passed through a 1 x 48 cm Sephadex G-50 column in Buffer A (PBS, 0.05% glycerol, 0.005 M EDTA, pH 7.6), and protein-containing fractions were pooled and assayed for thiolation, antigenicity, and molecular mass (Carlsson *et al.*, *Biochem. J.* 173:723-37, 1978).

5 Step 2: Conjugation of PDP-protein with Type I peptide

PDP-protein (24 mg) in 2 ml Buffer A was treated with 50 mM dithiothreitol for 30 minutes at room temperature and passed through a 1 x 48 cm Sephadex G-50 column in Buffer A. Fractions containing the 3-thiopropionyl- ϵ -Lys-NH₂-rPA (rPA-SH) were collected, concentrated to 1.5 ml and glycerol added to a final concentration of 3%. Br-Gly₃- γ -DPGA_n-C, 10 mg in 1 ml of Buffer A, was adjusted to pH 7.6 and rPA-SH added, incubated for 1 hour at room temperature (Inman *et al.*, *Bioconj. Chem.* 2:458-63, 1991), transferred to a vial, capped and tumbled overnight at room temperature. Bromoacetamide, 0.5 mg in 50 μ l Buffer A, was added to block unreacted thiols. After 30 minutes, the reaction mixture was passed through a 1 x 90 cm Sephacryl S-200 column in Buffer B (0.01 M phosphate, 0.2 M NaCl, 0.05% glycerol, pH 7.2). Fractions containing protein- γ PGA were pooled and assayed for peptide and protein concentration, antigenicity, and molecular mass.

15 Products:

BSA contained 60, rPA contained 58 and rEPA contained 15 moles Lys per mole of protein, respectively. Under these conditions, 28 of 60 ϵ -Lys-NH₂ of BSA, 50-55 of 58 of rPA and 15 of 15 of rEPA were derivatized with SPDP with retention of their antigenicity. Conjugation of BSA-SH, rPA-SH and rEPA-SH with Type I peptides yielded:

BSA-SH/Gly₃- γ -DPGA_n-C

BSA-SH/Gly₃- γ -LPGA_n-C

rEPA-SH/Gly₃- γ -DPGA_n-C

rPA-SH/Gly₃- γ -DPGA_n-C

25

Conjugation with Type II, III and VI peptides

Step 1: Derivatization of protein with SBAP

rPA or rEPA (30 mg) in 1.5 ml of Buffer A' was adjusted to pH 7.2. SBAP (11 mg) in 50 μ l DMSO was added in 10 μ l aliquots (Inman *et al.*, *Bioconj. Chem.* 2:458-63, 1991). After 60 minutes, the reaction mixture was passed through a 1 x 90 cm Sepharose CL-6B column in Buffer B. Fractions containing bromoacetamidopropionyl- ϵ -Lys-NH-rPA (Br-rPA) were collected and assayed for protein, free -NH₂, antigenicity, and molecular mass.

Step 2: Conjugation of Br-protein with Type II, III and VI peptides

Type II, III or VI peptides, 5 to 15 mg in Buffer A, were adjusted to pH 7.6 with 1 N NaOH. Br-protein (25 mg) in 1.5 ml Buffer A' was added. After 1 hour, the reaction mixture was transferred to a vial, capped, and tumbled overnight at room temperature. β -mercaptoethanol (1 μ l) was added to quench the remaining bromoacetyl groups in Br-protein. After 30 minutes, the reaction mixture was passed through 1 x 90 cm Sepharose CL-6B column in Buffer B. Fractions containing protein- γ PGA were pooled and assayed for peptide and protein concentration, antigenicity, and molecular mass.

Products:

Under these conditions, 50-55 of 58 and 15 of 15 residues of ϵ -Lys-NH₂ of *rPA* and *rEPA*, respectively, were modified with SBAP. *rPA*_{form} had 30 out of 58 ϵ -Lys-NH₂ free, and derivatization with SBAP converted essentially all 30 ϵ -Lys-NH₂ into the bromoacylated derivative, Br-*rPA*_{form}.

5 Conjugation of Br-*rPA* and Br-*rEPA* with Type II peptides yielded 4 conjugates:

rPA/S-Cys-Gly₃- γ DPGA_n-C
rPA/S-Cys-Gly₃- γ LPGA_n-C
rEPA/S-Cys-Gly₃- γ DPGA_n-C
rEPA/S-Cys-Gly₃- γ LPGA_n-C

10 Conjugation of Br-*rPA* and Br-*rEPA* with Type III peptides yielded 4 conjugates:

N- γ DPGA_n-Gly₃-Cys-S/*rPA*
N- γ LPGA_n-Gly₃-Cys-S/*rPA*
N- γ DPGA_n-Gly₃-Cys-S/*rEPA*
N- γ LPGA_n-Gly₃-Cys-S/*rEPA*

15 All eight conjugates precipitated with an identity reaction with their protein and γ PGA antisera by immunodiffusion. Representative analysis by MALDI-TOF is shown in FIG. 2.

Conjugation of Br-*rEPA* with Type VI peptide yielded:

rEPA/Cys- γ DPGA_n-N

Conjugation of Br-*rPA*_{form} with the N- γ DPGA_n-Gly₃-Cys Type III peptide yielded:

20 *rPA*_{form}/Cys-Gly₃- γ DPGA_n-N

Conjugation of Type IV peptide with BSA, rEPA and rPA via hydrazone linkage

4-formylbenzoyl- γ DPGA (CHO- γ DPGA) was bound to BSA-AH, *rEPA*-AH or *rPA*-AH in phosphate buffer, pH 7.0, at a molar ratio of CHO- γ DPGA to carrier protein-AH of 2:1 for 24-48 hours at room temperature. The reaction mixture was passed through a 1 x 90 cm Sepharose CL-6B column in 0.2 M phosphate buffer, pH 7.0, and fractions reacting with anti-carrier protein and anti- γ DPGA antibodies were pooled.

Conjugation of BSA-AH, *rEPA*-AH or *rPA*-AH with Type IV peptides yielded:

30 BSA-AH/CHO-Gly₃- γ DPGA_n-C
rEPA-AH/CHO-Gly₃- γ DPGA_n-C
rPA-AH/CHO-Gly₃- γ DPGA_n-C

*Conjugation of Type V peptide with BSA, rEPA, rPA, rPA*_{form} *via hydrazone linkage*

Step 1: Derivatization of BSA, *rEPA*, *rPA*, or *rPA*_{form} with SFB

35 To BSA (30 mg) in 1.2 ml of Buffer A containing 1 % glycerol, SFB (7.5 mg) in 100 μ l DMSO was added and reacted for 1 hour at pH 7.6. The product, 4-formylbenzoyl-BSA (CHO-BSA), was passed through a 1 x 48 cm Sephadex G-50 column in Buffer A. Protein containing fractions were pooled and assayed for the presence of benzoylaldehyde, antigenicity and protein concentration. For

rPA, *rEPA* and *rPA_{form}* derivatization with SFB was performed using 4 mg/ml *rPA*, *rEPA* and *rPA_{form}* respectively.

Step 2: Conjugation of CHO-BSA, CHO-*rEPA*, CHO-*rPA* or CHO-*rPA_{form}* with Type V peptides

5 To CHO-BSA, CHO-*rEPA*, CHO-*rPA* or CHO-*rPA_{form}* (20 mg) in 1.25 ml of Buffer A, 20 mg of Type V peptides dissolved in 400 μ l of 1M phosphate buffer, pH 7.4, was added. The pH of the reaction mixture was adjusted to 7.0 and incubated for 48-72 hours at room temperature. The mixture was passed through a 1 x 90 cm Sepharose CL-6B column in Buffer A, and fractions reacting with anti-carrier protein and anti- γ DPGA antibodies were pooled.

10 Products:

rPA_{form} had 30 out of 58 ϵ -Lys-NH₂ free (28 Lys were modified by the formaldehyde treatment), and the derivatization with SFB converted essentially all 30 ϵ -Lys-NH₂ into 4-formylbenzoyl-*rPA_{form}* (CHO-*rPA_{form}*). Conjugation of CHO-BSA, CHO-*rEPA*, CHO-*rPA* or CHO-*rPA_{form}* with Type V peptides yielded:

15 BSA-CHO/AH-Gly₃- γ DPGA_n-N
rEPA-CHO/AH- γ DPGA_n-N
rPA-CHO/AH- γ DPGA_n-N
rPA_{form}-CHO/AH-Gly₃- γ DPGA_n-N

20 *Conjugation of BSA-CHO/AH with Type IV peptide via hydrazone linkage*

Step 1: Derivatization of BSA with SLV

To BSA (56 mg) in 2.0 ml of Buffer A was added SLV (20 mg) in 200 μ l DMSO at pH 7.6 and reacted for 1 hour at room temperature. The product, BSA-LV-CHO, was passed through a 1 x 48 cm Sephadex G-50 column in Buffer A. Protein containing fractions were pooled and assayed for protein concentration.

25 Step 2: Derivatization of BSA-LV-CHO with ADH

BSA-LV-CHO (35 mg) in 1.5 ml of 0.2 M phosphate buffer, pH 6.0, was reacted with adipic acid dihydrazide (250 mg) at pH 6.0 in the presence of 100 μ l of borane-hydride-pyridine complex (800 μ moles) for 48 hours. The product, BSA-LV-CHO/AH, was passed through a 1 x 48 cm Sephadex G-30 column in Buffer A. BSA containing fractions were collected, analyzed for protein concentration, and the degree of -AH derivatization.

30 Step 3: Conjugation of BSA-LV-CHO/AH with Type IV peptide

BSA-LV-CHO/AH (20 mg) in 1.5 ml of 0.2 M phosphate buffer, pH 6.0, was mixed with 10 mg Type IV peptide, pH 6.0. After 60 minutes, 100 μ l of borane-hydride-pyridine complex (800 μ moles) was added, and after 48 hours the product was passed through a 1 x 48 cm Sephadex G-50 column in Buffer A. Fractions reacting with anti-BSA and anti- γ DPGA antibodies were pooled.

Conjugation of BSA-LV-CHO/AH with Type IV peptide yielded:

BSA-SL-AH/CHO-Gly₃- γ DPGA_n-C

Immunization

Five- to six-week old female NIH GP mice were immunized s.c. 3 times at 2-week intervals with 2.5 μg γPGA as a conjugate in 0.1 ml of PBS, and groups of 10 mice were exsanguinated 7 days after the second or third injections (Schneerson *et al.*, *J. Exp. Med.* 152:361-76, 1980). Controls received PBS.

Antibodies

Serum IgG antibodies were measured by ELISA (Taylor *et al.*, *Infect. Immun.* 61:3678-87, 1993). Nunc Maxisorb plates were coated with γDPGA , 20 $\mu\text{g}/\text{ml}$ PBS or 4 μg $r\text{PA}/\text{ml}$ PBS. Plates were blocked with 0.5% BSA (or with 0.5% HSA for assay of BSA conjugates) in PBS for 2 hours at room temperature. A MRX Dynatech reader was used. Antibody levels were calculated relative to standard sera: for γDPGA , a hyperimmune murine serum, prepared by multiple i.p. injections of formalin-treated *B. anthracis* strain A34 and assigned a value of 100 ELISA units (EU), for PA a mAb containing 4.7 mg Ab/ml (Little *et al.*, *Infect. Immun.* 56:1807-13, 1988). Results were computed with an ELISA data processing program provided by the Biostatistics and Information Management Branch, CDC (Plikaytis *et al.*, *User's Manual 12* CDC, Version 1.00, 1996). IgG levels are expressed as geometric mean (GM).

Opsonophagocytosis

Spores of *B. anthracis*, strain A34, were maintained at 5×10^8 spores per ml in 1% phenol. The human cell line, HL-60 (CCL240, ATCC, Rockville, MD) was expanded and differentiated by dimethyl formamide into 44% myelocytes and metamyelocytes, and 53% band and polymorphonuclear leukocytes (PMLs). PMLs were at an effector/target cell ratio of 400:1. PMLs were centrifuged and resuspended in opsonophagocytosis buffer (Hanks' buffer with Ca^{2+} , Mg^{2+} and 0.1% gelatin (Life Technologies, Grand Island, NY)) at 2×10^7 cells per ml. Spores were cultured at 5×10^7 spores per ml for 3 hours in 20% CO_2 , and diluted to 5×10^4 spores per ml. Sera were diluted 2-fold with 0.05 ml of opsonophagocytosis buffer, and 0.02 ml (containing approximately 10^3 bacteria) were added to each well of a 24-well tissue culture plate (Falcon, Franklin Lakes, NJ). The plates were incubated at 37°C in 5% CO_2 for 15 min. A 0.01 ml of aliquot of colostrum-deprived baby calf serum (complement) and 0.02 ml of HL-60 suspension containing 4×10^5 cells was added to each well, and incubated at 37°C in 5% CO_2 with mixing at 220 rpm for 45 minutes. A 0.01 ml aliquot from each well was added to tryptic soy agar at 50°C , and CFU determined the next morning.

Opsonophagocytosis was defined by $\geq 50\%$ killing compared with the growth in control wells (Romero-Steiner *et al.*, *Clin. Diagn. Lab. Immunol.* 4:415-33, 1997).

Statistics

ELISA values are expressed as the GM. An unpaired *t* test was used to compare GMs in different groups of mice.

Example 2

Serum IgG Anti- γ DPGA Antibodies

5 This example demonstrates that conjugates of *B. anthracis* γ DPGA and of *B. pumilus* γ D/LPGA elicited IgG anti- γ DPGA antibodies.

Native γ DPGA from the capsule of *B. anthracis* elicited trace levels of antibodies after the third injection (Table 1). All the conjugates, in contrast, elicited IgG anti- γ DPGA antibodies after two injections (Table 1). Conjugates of *B. anthracis* γ DPGA and of *B. pumilus* γ D(60%)/L(40%)PGA elicited IgG anti- γ DPGA antibodies of intermediate levels after two injections with a booster after the
10 third (Table 1). However, precipitates were formed during the synthesis of both conjugates, resulting in low yields. This problem was not encountered when preparing the synthetic γ PGA conjugates.

The highest levels of anti- γ DPGA antibodies were achieved with peptide decamers at a density (peptide chains to carrier molecule) of 16:1 for *r*PA/Cys-Gly₃- γ DPGA₁₀-C, and of 11:1 and 14:1 for *r*PA-SH/Gly₃- γ DPGA₁₀-C (Table 1). *r*PA was a more effective carrier than *r*EPA or BSA (Table 1).
15 With the exception of *r*PA-SH/Gly₃- γ DPGA₁₀-C, with 11 chains per carrier protein, all conjugates elicited a rise in anti- γ DPGA antibodies after the third injection (Table 1). Conjugates prepared with L peptides bound at either the C- or N-terminus induced low levels of IgG anti- γ DPGA antibodies (Table 1).

Table 1. Composition and serum geometric mean IgG anti- γ DPGA and anti-carrier protein antibodies elicited in mice by conjugates of γ PGA with BSA, rEPA and rPA.

Conjugate	Mol γ DPGA per mol protein	Protein per γ DPGA (wt/wt)	Anti- γ DPGA*		Anti-protein†	
			Second injection	Third injection	Second injection	Third injection
γ DPGA- <i>B. anthracis</i>	NA‡	NA	0.3	4.4	NA	NA
rEPA-AH/ γ DPGA- <i>B. anthracis</i>	NA	1:0.29	695	2312	ND§	ND
rPA-AH γ DPGA- <i>B. anthracis</i>	NA	1:4.42	1325	3108	ND	ND
BSA-SH/Gly ₃ - γ DPGA ₁₀ -C¶	7	1:0.14	134	1984	ND	ND
BSA-SH/Gly ₃ - γ DPGA ₁₀ -C	18	1:0.35	1882	1821	ND	ND
BSA-SH/Gly ₃ - γ DPGA ₁₀ -C	25	1:0.49	2063	2780	ND	ND
BSA-SH/Gly ₃ - γ LPGA ₁₀ -C	7	1:0.14	261	618	ND	ND
rEPA/Cys-Gly ₃ - γ DPGA ₁₀ -C	7	1:0.14	479	4470	ND	ND
rEPA-SH/Gly ₃ - γ DPGA ₅ -C	17	1:0.17	502	1168	ND	ND
rEPA-SH/Gly ₃ - γ DPGA ₁₀ -C	9	1:0.18	931	3193	ND	ND
rEPA-SH/Gly ₃ - γ DPGA ₂₀ -C	5	1:0.19	749	2710	ND	ND
rPA/Cys-Gly ₃ - γ DPGA ₅ -C	32	1:0.26	2454	4560	0.06	8.5
rPA/Cys-Gly ₃ - γ DPGA ₁₀ -C	16	1:0.26	9091	11268	1.30	59.3
rPA/Cys-Gly ₃ - γ DPGA ₂₀ -C	14	1:0.44	742	3142	0.01	4.5
rPA/Cys-Gly ₃ - γ DPGA ₅ -N	22	1:0.18	3149	3460	3.70	95.0
rPA/Cys-Gly ₃ - γ DPGA ₁₀ -N	21	1:0.33	5489	7516	0.10	2.2
rPA/Cys-Gly ₃ - γ DPGA ₂₀ -N	8	1:0.25	2630	5461	0.05	4.9
rPA-SH/Gly ₃ - γ DPGA ₅ -C	15	1:0.12	1813	3607	0.27	19.7
rPA-SH/Gly ₃ - γ DPGA ₁₀ -C	11	1:0.18	10460	9907	0.50	102.0
rPA-SH/Gly ₃ - γ DPGA ₁₀ -C	14	1:0.22	4378	7206	0.34	66.3
rPA-SH/Gly ₃ - γ DPGA ₂₀ -C	4	1:0.13	2655	4069	0.90	32.2
rPA-SH/Gly ₃ - γ DPGA ₂₀ -C	8	1:0.25	9672	7320	0.22	189.0
rPA/Cys-Gly ₃ - γ LPGA ₂₀ -N	22	1:0.70	24	79	0.14	3.0
rPA/Cys-Gly ₃ - γ LPGA ₂₀ -C	24	1:0.76	155	437	0.31	7.8
BSA-AH/CHO-Gly ₃ - γ DPGA ₁₀ -C	12	1:0.23	1476	3354	ND	ND
rEPA-AH/CHO-Gly ₃ - γ DPGA ₁₀ -C	8	1:0.15	807	2099	1	14
rPA-AH/CHO-Gly ₃ - γ DPGA ₁₀ -C	22	1:0.34	ND	ND	ND	ND
BSA-CHO/AH-Gly ₃ - γ DPGA ₁₀ -N	8	1:0.17	185	1139	ND	ND
rEPA-CHO/AH- γ DPGA ₁₅ -N	6	1:0.18	ND	ND	ND	ND
rPA-CHO/AH- γ DPGA ₁₅ -N	5	1:0.12	ND	ND	ND	ND
rPA _{form} -CHO/AH-Gly ₃ - γ DPGA ₁₀ -N	29	1:0.45	ND	ND	ND	ND
BSA-SL-AH/CHO- Gly ₃ - γ DPGA ₁₀ -C	3	1:0.06	103	822	ND	ND
rEPA/Cys- γ DPGA ₁₅ -N	ND	ND	ND	ND	ND	ND
rPA _{form} /Cys-Gly ₃ - γ DPGA ₁₀ -N	15	1:0.23	ND	ND	ND	ND

* γ DPGA from *B. anthracis* (strain A34), 2.5 μ g as a conjugate used for injection; antibodies by ELISA expressed as EU.

†Antibodies by ELISA expressed as μ g Ab/ml.

‡Not applicable

§Not done

¶C or N refers to the free amino acid on the γ PGA bound to the protein.

A dose response of two γ DPGA conjugates with *r*PA and *r*EPA as the carrier showed that *r*PA was a more effective carrier than *r*EPA (Table 2). Both peptides had 20 glutamic acid residues, and similar number of chains per carrier protein. The lowest dose (2.5 μ g) of *r*PA-SH/Gly₃- γ DPGA-C elicited the highest level of IgG anti- γ DPGA antibodies (9,133 EU, Table 2). The levels declined about half that at the 20 μ g dose (Table 2). *r*EPA-SH/Gly₃- γ DPGA-C, in contrast, elicited similar levels at all dosages (Table 2).

Table 2. Dose/immunogenicity relation of conjugates prepared with 20-mers of γ DPGA bound to *r*PA or *r*EPA.

Conjugate	Mol γ DPGA/ mol protein	Protein/ γ DPGA (wt/wt)	Dose/ mice (μ g γ DPGA)	Anti- γ DPGA 3 rd injection
<i>r</i> PA-SH/Gly ₃ - γ DPGA ₂₀ -C	8	1:0.25	2.5	9152
			5	7070
			10	3487
			20	4901
<i>r</i> EPA-SH/Gly ₃ - γ DPGA ₂₀ -C	6	1:0.23	2.5	1956
			5	2393
			10	2639
			20	2834

Five- to six-week old NIH general purpose mice ($n = 10$) injected s.c. with 0.1 ml of the conjugates two weeks apart and exsanguinated seven days after the third injection. IgG anti- γ DPGA was measured by ELISA and the results expressed as the geometric mean (9,152 vs. 3,487, $P=0.003$; 9,152 vs. 4,901, $P=0.04$; 9,152 vs. 1,956, $P<0.0001$; 7,070 vs. 2,393, $P<0.0001$).

The relationship between γ DPGA conjugate dosage and immunogenicity was further examined using a γ DPGA-*r*PA conjugate (*r*PA/Cys-Gly₃- γ DPGA₁₀-N, with 22 chains per carrier protein) at doses ranging from 2.5 μ g to 0.31 μ g per mouse (with 20 μ g per mouse for comparison). The optimal response to γ DPGA was at 1.25 μ g per mouse (Table 3). The response to *r*PA increased with a higher immunizing dose (Table 3).

Table 3. Dose/immunogenicity relation of conjugate prepared with 10-mer of γ DPGA bound to *r*PA.

Dose μ g/mouse	Anti- γ DPGA		Anti- <i>r</i> PA	
	2 nd injection	3 rd injection	2 nd injection	3 rd injection
20	-	3716	-	437
2.5	2231	5812	2	206
1.25	2314	6241	2	118
0.63	984	4943	0.6	37
0.31	493	3480	0.3	9

The effect of adjuvant on immunogenicity was studied using two γ DPGA-*r*PA conjugates. Injection of the conjugate with aluminum hydroxide improved significantly the immune response to *r*PA (Table 4). The anti- γ DPGA levels were not statistically different (Table 4).

Table 4. Formulation effect.

Conjugate	Dose μg/mouse	Anti- γDPGA		Anti-rPA	
		2 nd injection	3 rd injection	2 nd injection	3 rd injection
rPA/Cys-Gly ₃ - γDPGA ₁₀ -N	2.5	2231	5812	2	206
	2.5 + al*	3527	6231	80	282
rPA/Cys-Gly ₃ - γDPGA ₁₀ -C	2.5	1041	2315	1	185
	1	-	2880	-	61
	1+form**	-	2556	-	23
	1+al	-	3975	-	258
	1+form/al	-	3268	-	297

* aluminum hydroxide (Alhydrogel)

** formaldehyde treatment (Porro *et al.*, *J. Infect. Dis.* 142:716-24, 1980; Nencioni *et al.*, *Infect. Immun.* 59:625-30, 1991).

5

Example 3

Serum IgG Anti-Carrier Protein Antibodies

This example demonstrates that conjugates of *B. anthracis* γDPGA elicited IgG anti-carrier protein antibodies in addition to anti-γDPGA antibodies.

With few exceptions, both the length and number of γDPGA chains per carrier protein were related to the level of IgG anti-carrier protein antibodies (Table 1). Conjugates prepared with γDPGA polypeptides containing 20 residues elicited low levels of carrier protein antibodies (Table 1). Conjugates prepared with either 5 or 10 glutamic acid residues per chain, and conjugates with ≤15 chains per carrier protein elicited the highest levels of IgG carrier protein antibodies (Table 1).

15

Example 4

Opsonophagocytic Activity of Mouse Antisera

This example demonstrates that IgG anti-γDPGA antibodies have opsonophagocytic activity. Sera from normal mice or those immunized with rEPA or rPA did not have opsonophagocytic activity. However, in mice immunized with BSA-SH/Gly₃-γDPGA₁₀-C or BSA-SH/Gly₃-γDPGA₁₀-C there was a correlation between the level of IgG anti-γDPGA antibodies and opsonophagocytosis ($r=0.7$, $P=0.03$, Table 5). Addition of γDPGA from *B. anthracis* to the immune sera showed a dose-related reduction of the opsonophagocytic titer of approximately 60%.

25

Table 5. Opsonophagocytic activity and IgG anti- γ DPGA antibodies (ELISA) elicited by BSA-SH/Gly₃- γ DPGA₁₀-C.

Sera	IgG anti- γ DPGA	Reciprocal opsonophagocytic titer
1196G	407	Not detected
1195C	1,147	640
1197B	3,975	2,560
1190H	3,330	2,560
1194D	3,278	2,560
1193B	3,178	2,560
1194G	3,277	2,560
1191J	5,191	5,120

Correlation coefficient between ELISA and reciprocal opsonophagocytic titer is 0.7, $P=0.03$.

5

Example 5

Methods for Preparing Peptide and Protein Mimetics

This example describes methods for preparing peptide and protein mimetics modified at the N-terminal amino group, the C-terminal carboxyl group, and/or changing one or more of the amido linkages in the peptide to a non-amido linkage. It is understood that two or more such modifications can be coupled in one peptide or protein mimetic structure (for example, modification at the C-terminal carboxyl group and inclusion of a --CH₂ -carbamate linkage between two amino acids in the peptide).

For N-terminal modifications, peptides typically are synthesized as the free acid but, as noted above, can be readily prepared as the amide or ester. One can also modify the amino and/or carboxy terminus of peptide compounds to produce other compounds useful within the disclosure. Amino terminus modifications include methylating (that is, --NHCH₃ or --NH(CH₃)₂), acetylating, adding a carbobenzoyl group, or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO--, where R is selected from the group consisting of naphthyl, acridinyl, steroidyl, and similar groups. Carboxy terminus modifications include replacing the free acid with a carboxamide group or forming a cyclic lactam at the carboxy terminus to introduce structural constraints. Amino terminus modifications are as recited above and include alkylating, acetylating, adding a carbobenzoyl group, forming a succinimide group, and the like. The N-terminal amino group can then be reacted as follows: (A) to form an amide group of the formula RC(O)NH-- where R is as defined above by reaction with an acid halide (for example, RC(O)Cl) or acid anhydride. Typically, the reaction can be conducted by contacting about equimolar or excess amounts (for example, about 5 equivalents) of an acid halide to the peptide in an inert diluent (for example, dichloromethane) preferably containing an excess (for example, about 10 equivalents) of a tertiary amine, such as diisopropylethylamine, to scavenge the acid generated during reaction. Reaction conditions are otherwise conventional (for example, room temperature for 30 minutes). Alkylation of the terminal

amino to provide for a lower alkyl N-substitution followed by reaction with an acid halide as described above will provide for N-alkyl amide group of the formula $RC(O)NR--$. (B) to form a succinimide group by reaction with succinic anhydride. As before, an approximately equimolar amount or an excess of succinic anhydride (for example, about 5 equivalents) can be employed and the amino group is converted to the succinimide by methods well known in the art including the use of an excess (for example, ten equivalents) of a tertiary amine such as diisopropylethylamine in a suitable inert solvent (for example, dichloromethane) (see, for example, U.S. Pat. No. 4,612,132). It is understood that the succinic group can be substituted with, for example, C2 -C6 alkyl or --SR substituents that are prepared in a conventional manner to provide for substituted succinimide at the N-terminus of the peptide. Such alkyl substituents are prepared by reaction of a lower olefin (C2 -C6) with maleic anhydride in the manner described by Wollenberg *et al.* (U.S. Pat. No. 4,612,132) and --SR substituents are prepared by reaction of RSH with maleic anhydride where R is as defined above. (C) to form a benzyloxycarbonyl--NH-- or a substituted benzyloxycarbonyl--NH-- group by reaction with approximately an equivalent amount or an excess of CBZ-Cl (that is, benzyloxycarbonyl chloride) or a substituted CBZ-Cl in a suitable inert diluent (for example, dichloromethane) preferably containing a tertiary amine to scavenge the acid generated during the reaction. (D) to form a sulfonamide group by reaction with an equivalent amount or an excess (for example, 5 equivalents) of $R-S(O)_2Cl$ in a suitable inert diluent (for example, dichloromethane) to convert the terminal amine into a sulfonamide where R is as defined above. Preferably, the inert diluent contains excess tertiary amine (for example, ten equivalents) such as diisopropylethylamine, to scavenge the acid generated during reaction. Reaction conditions are otherwise conventional (for example, room temperature for 30 minutes). (E) to form a carbamate group by reaction with an equivalent amount or an excess (for example, 5 equivalents) of $R-OC(O)Cl$ or $R-OC(O)OC_6H_4-p-NO_2$ in a suitable inert diluent (for example, dichloromethane) to convert the terminal amine into a carbamate where R is as defined above. Preferably, the inert diluent contains an excess (for example, about 10 equivalents) of a tertiary amine, such as diisopropylethylamine, to scavenge any acid generated during reaction. Reaction conditions are otherwise conventional (for example, room temperature for 30 minutes). (F) to form a urea group by reaction with an equivalent amount or an excess (for example, 5 equivalents) of $R--N=C=O$ in a suitable inert diluent (for example, dichloromethane) to convert the terminal amine into a urea (that is, $RNHC(O)NH--$) group where R is as defined above. Preferably, the inert diluent contains an excess (for example, about 10 equivalents) of a tertiary amine, such as diisopropylethylamine. Reaction conditions are otherwise conventional (for example, room temperature for about 30 minutes).

In preparing peptide mimetics wherein the C-terminal carboxyl group is replaced by an ester (that is, $--C(O)OR$ where R is as defined above), resins as used to prepare peptide acids are typically employed, and the side chain protected peptide is cleaved with base and the appropriate alcohol, for example, methanol. Side chain protecting groups are then removed in the usual fashion by treatment with hydrogen fluoride to obtain the desired ester.

In preparing peptide mimetics wherein the C-terminal carboxyl group is replaced by the amide --C(O)NR₃R₄, a benzhydrylamine resin is used as the solid support for peptide synthesis. Upon completion of the synthesis, hydrogen fluoride treatment to release the peptide from the support results directly in the free peptide amide (that is, the C-terminus is --C(O)NH₂). Alternatively, use of the

5 chloromethylated resin during peptide synthesis coupled with reaction with ammonia to cleave the side chain protected peptide from the support yields the free peptide amide and reaction with an alkylamine or a dialkylamine yields a side chain protected alkylamide or dialkylamide (that is, the C-terminus is --C(O)NRR₁ where R and R₁ are as defined above). Side chain protection is then removed in the usual fashion by treatment with hydrogen fluoride to give the free amides, alkylamides, or dialkylamides.

10 In other embodiments of the disclosure, the C-terminal carboxyl group or a C-terminal ester of a biologically active peptide can be induced to cyclize by internal displacement of the --OH or the ester (--OR) of the carboxyl group or ester respectively with the N-terminal amino group to form a cyclic peptide. For example, after synthesis and cleavage to give the peptide acid, the free acid is converted to an activated ester by an appropriate carboxyl group activator such as dicyclohexylcarbodiimide in

15 solution, for example, in methylene chloride (CH₂Cl₂), dimethyl formamide mixtures. The cyclic peptide is then formed by internal displacement of the activated ester with the N-terminal amine. Internal cyclization as opposed to polymerization can be enhanced by use of very dilute solutions. Such methods are well known in the art.

One can cyclize active peptides for use within the disclosure, or incorporate a desamino or

20 descarboxy residue at the termini of the peptide, so that there is no terminal amino or carboxyl group, to decrease susceptibility to proteases, or to restrict the conformation of the peptide. C-terminal functional groups among peptide analogs and mimetics of the present disclosure include amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof.

25 Other methods for making peptide and protein derivatives and mimetics for use within the methods and compositions of the disclosure are described in Hruby *et al.*, (*Biochem. J.* 268:249-62, 1990). According to these methods, biologically active peptides and proteins serve as structural models for non-peptide mimetic compounds having similar biological activity as the native peptide or protein. Those of skill in the art recognize that a variety of techniques are available for constructing compounds

30 with the same or similar desired biological activity as the lead peptide or protein compound, or that have more favorable activity than the lead with respect a desired property such as solubility, stability, and susceptibility to hydrolysis and proteolysis (see, for example, Morgan and Gainor, *Ann. Rep. Med. Chem.* 24:243-52, 1989). These techniques include, for example, replacing a peptide backbone with a backbone composed of phosphonates, amidates, carbamates, sulfonamides, secondary amines, and/or

35 N-methylamino acids.

Peptide and protein mimetics wherein one or more of the peptidyl linkages (--C(O)NH--) have been replaced by such linkages as a --CH₂-carbamate linkage, a phosphonate linkage, a --CH₂-sulfonamide linkage, a urea linkage, a secondary amine (--CH₂NH--) linkage, and an alkylated peptidyl

linkage ($--C(O)NR_6$ -- where R_6 is lower alkyl) are prepared, for example, during conventional peptide synthesis by merely substituting a suitably protected amino acid analogue for the amino acid reagent at the appropriate point during synthesis. Suitable reagents include, for example, amino acid analogues wherein the carboxyl group of the amino acid has been replaced with a moiety suitable for forming one of the above linkages. For example, if one desires to replace a $--C(O)NR--$ linkage in the peptide with a $--CH_2$ -carbamate linkage ($--CH_2OC(O)NR--$), then the carboxyl ($--COOH$) group of a suitably protected amino acid is first reduced to the $--CH_2OH$ group which is then converted by conventional methods to a $--OC(O)Cl$ functionality or a para-nitrocarbonate $--OC(O)O-C_6H_4-p-NO_2$ functionality. Reaction of either of such functional groups with the free amine or an alkylated amine on the N-terminus of the partially fabricated peptide found on the solid support leads to the formation of a $--CH_2OC(O)NR--$ linkage. For a more detailed description of the formation of such $--CH_2$ -carbamate linkages, see, for example, Cho *et al.*, *Science* 261:1303-05, 1993.

Replacement of an amido linkage in an active peptide with a $--CH_2$ -sulfonamide linkage can be achieved by reducing the carboxyl ($--COOH$) group of a suitably protected amino acid to the $--CH_2OH$ group, and the hydroxyl group is then converted to a suitable leaving group such as a tosyl group by conventional methods. Reaction of the derivative with, for example, thioacetic acid followed by hydrolysis and oxidative chlorination will provide for the $--CH_2--S(O)_2Cl$ functional group which replaces the carboxyl group of the otherwise suitably protected amino acid. Use of this suitably protected amino acid analogue in peptide synthesis provides for inclusion of an $--CH_2S(O)_2NR--$ linkage that replaces the amido linkage in the peptide thereby providing a peptide mimetic. For a more complete description on the conversion of the carboxyl group of the amino acid to a $--CH_2S(O)_2Cl$ group, see, for example, Weinstein and Boris, *Chemistry & Biochemistry of Amino Acids, Peptides and Proteins*, Vol. 7, pp. 267-357, Marcel Dekker, Inc., New York, 1983. Replacement of an amido linkage in an active peptide with a urea linkage can be achieved, for example, in the manner set forth in U.S. Patent Application Ser. No. 08/147,805.

Secondary amine linkages wherein a $--CH_2NH--$ linkage replaces the amido linkage in the peptide can be prepared by employing, for example, a suitably protected dipeptide analogue wherein the carbonyl bond of the amido linkage has been reduced to a CH_2 group by conventional methods. For example, in the case of diglycine, reduction of the amide to the amine will yield after deprotection $H_2NCH_2CH_2NHCH_2COOH$ that is then used in N-protected form in the next coupling reaction. The preparation of such analogues by reduction of the carbonyl group of the amido linkage in the dipeptide is well known in the art.

The biologically active peptide and protein agents of the present disclosure can exist in a monomeric form with no disulfide bond formed with the thiol groups of cysteine residue(s) that may be present in the subject peptide or protein. Alternatively, an intermolecular disulfide bond between thiol groups of cysteines on two or more peptides or proteins can be produced to yield a multimeric (for example, dimeric, tetrameric or higher oligomeric) compound. Certain of such peptides and proteins can be cyclized or dimerized via displacement of the leaving group by the sulfur of a

cysteine or homocysteine residue (see, for example, Barker *et al.*, *J. Med. Chem.* 35:2040-48, 1992 and Or *et al.*, *J. Org. Chem.* 56:3146-49, 1991). Thus, one or more native cysteine residues can be substituted with a homocysteine. Intramolecular or intermolecular disulfide derivatives of active peptides and proteins provide analogs in which one of the sulfurs has been replaced by a CH₂ group or other isostere for sulfur. These analogs can be made via an intramolecular or intermolecular displacement, using methods known in the art.

Example 6

Delivery of γ PGA Conjugates

This example demonstrates that delivery of γ PGA conjugates can be enhanced by methods and agents that target selective transport mechanisms and promote endo- or transcytosis of macromolecular drugs.

In this regard, the compositions and delivery methods of the disclosure optionally incorporate a selective transport-enhancing agent that facilitates transport of one or more biologically active agents. These transport-enhancing agents can be employed in a combinatorial formulation or coordinate administration protocol with one or more of the peptides, proteins, analogs and mimetics disclosed herein, to coordinately enhance delivery of the biologically active agent(s) into target cells. Exemplary selective transport-enhancing agents for use within this aspect of the disclosure include, but are not limited to, glycosides, sugar-containing molecules, and binding agents such as lectin binding agents, which are known to interact specifically with epithelial transport barrier components (see, for example, Goldstein *et al.*, *Annu. Rev. Cell. Biol.* 1:1-39, 1985). For example, specific "bioadhesive" ligands, including various plant and bacterial lectins, which bind to cell surface sugar moieties by receptor-mediated interactions can be employed as carriers or conjugated transport mediators for enhancing delivery of γ PGA conjugates within the disclosure. Certain bioadhesive ligands for use within the disclosure will mediate transmission of biological signals to epithelial target cells that trigger selective uptake of the adhesive ligand by specialized cellular transport processes (endocytosis or transcytosis). These transport mediators can therefore be employed as a "carrier system" to stimulate or direct selective uptake of a γ PGA conjugate within the methods of the disclosure. To utilize these transport-enhancing agents, general carrier formulation and/or conjugation methods known in the art are used to complex or otherwise coordinately administer a selective transport enhancer (for example, a receptor-specific ligand) and a γ PGA conjugate to trigger or mediate enhanced endo- or transcytosis of the γ PGA conjugate into specific target cell(s), tissue(s) or compartment(s).

Lectins are plant proteins that bind to specific sugars found on the surface of glycoproteins and glycolipids of eukaryotic cells. Concentrated solutions of lectins have a "mucottractive" effect, and various studies have demonstrated rapid receptor mediated endocytosis of lectins and lectin conjugates (for example, concanavalin A conjugated with colloidal gold particles) across mucosal surfaces. Additional studies have reported that the uptake mechanisms for lectins can be utilized for intestinal drug targeting *in vivo*. In certain of these studies, polystyrene nanoparticles (500 nm) were covalently

coupled to tomato lectin and reported yielded improved systemic uptake after oral administration to rats. In addition to plant lectins, microbial adhesion and invasion factors provide a rich source of candidates for use as adhesive/selective transport carriers within the compositions and methods of the disclosure (see, for example, Lehr, *Crit. Rev. Therap. Drug Carrier Syst.* 11:177-218, 1995 and Swann, 5 *Pharmaceutical Research* 15:826-32, 1998). Two components are necessary for bacterial adherence processes, a bacterial "adhesin" (adherence or colonization factor) and a receptor on the host cell surface. Bacteria causing mucosal infections need to penetrate the mucus layer before attaching themselves to the epithelial surface. This attachment is usually mediated by bacterial fimbriae or pilus structures, although other cell surface components can also take part in the process. Adherent bacteria 10 colonize mucosal epithelia by multiplication and initiation of a series of biochemical reactions inside the target cell through signal transduction mechanisms (with or without the help of toxins).

Associated with these invasive mechanisms, a wide diversity of bioadhesive proteins (for example, invasins, internalins) originally produced by various bacteria and viruses are known. These allow for extracellular attachment of such microorganisms with an impressive selectivity for host 15 species and even particular target tissues. Signals transmitted by such receptor-ligand interactions trigger the transport of intact, living microorganisms into, and eventually through, epithelial cells by endo- and transcytotic processes. Such naturally occurring phenomena can be harnessed (for example, by complexing a γ PGA conjugate with an adhesin) according to the teachings herein for enhanced delivery of γ PGA conjugates and/or other biologically active compounds. One advantage of this 20 strategy is that the selective carrier partners thus employed are substrate-specific, leaving the natural barrier function of epithelial tissues intact against other solutes (see, for example, Lehr, *Drug Absorption Enhancement*, pp. 325-362, de Boer, Ed., Harwood Academic Publishers, 1994).

Various bacterial and plant toxins that bind epithelial surfaces in a specific, lectin-like manner are also useful within the methods and compositions of the disclosure. For example, diphtheria toxin 25 enters host cells rapidly by receptor mediated endocytosis. Likewise, the B subunit of the *E. coli* heat labile toxin binds to the brush border of intestinal epithelial cells in a highly specific, lectin-like manner. Uptake of this toxin and transcytosis to the basolateral side of the enterocytes has been reported *in vivo* and *in vitro*. Other researches have expressed the transmembrane domain of diphtheria toxin in *E. coli* as a maltose-binding fusion protein and coupled it chemically to high-Mw poly-L- 30 lysine. The resulting complex was successfully used to mediate internalization of a reporter gene *in vitro*. In addition to these examples, *Staphylococcus aureus* produces a set of proteins (for example, staphylococcal enterotoxin A, staphylococcal enterotoxin B and toxic shock syndrome toxin 1) which act both as superantigens and toxins. Studies relating to these proteins have reported dose-dependent, facilitated transcytosis of staphylococcal enterotoxin B and toxic shock syndrome toxin 1 in Caco-2 35 cells.

Various plant toxins, mostly ribosome-inactivating proteins, have been identified that bind to any mammalian cell surface expressing galactose units and are subsequently internalized by receptor mediated endocytosis. Toxins such as nigrin b, sarcin, ricin and saporin, viscumin, and modeccin are

highly toxic upon oral administration (that is, they are rapidly internalized). Therefore, modified, less toxic subunits of these compound will be useful within the disclosure to facilitate the uptake of γ PGA conjugates and other biologically active agents, including PA, other bacterial products and analogs, variants, derivatives and mimetics thereof.

5 Viral hemagglutinins include another type of transport agent to facilitate delivery of γ PGA conjugates and other biologically active agents within the methods and compositions of the disclosure. The initial step in many viral infections is the binding of surface proteins (hemagglutinins) to mucosal cells. These binding proteins have been identified for most viruses, including rotaviruses, *Varicella*
10 *zoster* virus, semliki forest virus, adenoviruses, potato leafroll virus, and reovirus. These and other exemplary viral hemagglutinins can be employed in a combinatorial formulation (for example, a mixture or conjugate formulation) or coordinate administration protocol with, for example, one or more γ PGA conjugates, PA immunogens, other bacterial products, or analogs, variants, derivatives and mimetics thereof. Alternatively, viral hemagglutinins can be employed in a combinatorial formulation or coordinate administration protocol to directly enhance delivery of a γ PGA conjugate or other
15 biologically active agent within the disclosure.

A variety of endogenous, selective transport-mediating factors are also available for use within the disclosure. Exemplary among these are protocytoic transport carriers within the folate carrier system, which mediate transport of the vitamin folic acid into target cells via specific binding to the folate receptor (see, for example, Reddy *et al.*, *Crit. Rev. Ther. Drug Car. Syst.* 15:587-27, 1998). This
20 receptor system has been used in drug-targeting approaches to cancer cells, but also in protein delivery, gene delivery, and targeting of antisense oligonucleotides to a variety of cell types. Folate-drug conjugates are well suited for use within the methods and compositions of the disclosure, because they allow penetration of target cells exclusively via folate receptor-mediated endocytosis. When folic acid is covalently linked to a biologically active agent, folate receptor binding affinity ($K_D \sim 10^{-10}M$) is not
25 significantly compromised, and endocytosis proceeds relatively unhindered, promoting uptake of the attached active agent by the folate receptor-expressing cell.

In addition to the folate receptor pathway, a variety of additional methods to stimulate transcytosis within the disclosure are directed to the transferrin receptor pathway, and the riboflavin receptor pathway. In one aspect, conjugation of a γ PGA conjugate or other biologically active agent to
30 riboflavin can effectuate receptor mediated endocytosis uptake. Yet additional embodiments of the disclosure utilize vitamin B12 (cobalamin) as a specialized transport protein (for example, conjugation partner) to facilitate entry of γ PGA conjugates and other biologically active agents into target cells. Certain studies suggest that this particular system can be employed for mucosal delivery into the intestine. Still other embodiments of the disclosure utilize transferrin as a carrier or stimulant of
35 receptor mediated endocytosis of mucosally delivered biologically active agents. Transferrin, an 80 kDa iron-transporting glycoprotein, is efficiently taken up into cells by receptor mediated endocytosis. Transferrin receptors are found on the surface of most proliferating cells, in elevated numbers on erythroblasts and on many kinds of tumors. Each of the foregoing agents that stimulate receptor-

mediated transport can be employed within the methods of the disclosure as combinatorially formulated (for example, conjugated) and/or coordinately administered agents to enhance receptor-mediated transport of γ PGA conjugates and other biologically active agents, including, PA, carriers, linkers, and other bacterial toxins and analogs, variants, derivatives and mimetics thereof.

5 Immunoglobulin transport mechanisms provide yet additional endogenous pathways and reagents for enhancing delivery of γ PGA conjugates and other active agents within the methods and compositions of the disclosure. Receptor-mediated transcytosis of immunoglobulin G (IgG) across the neonatal small intestine serves to convey passive immunity to many newborn mammals. Within the methods and compositions of the present disclosure, IgG and other immune system-related carriers
10 (including polyclonal and monoclonal antibodies and various fragments thereof) can be complexed or otherwise coordinately administered with γ PGA conjugates and other biologically active agents to provide for targeted delivery, typically by receptor-mediated transport. For example, the γ PGA conjugate or other biologically active agent can be covalently linked to the IgG or other immunological active agent or, alternatively, formulated in liposomes or other carrier vehicle which is in turn modified
15 (for example, coated or covalently linked) to incorporate IgG or other immunological transport enhancer. In certain embodiments, polymeric IgA and/or IgM transport agents are employed, which bind to the polymeric immunoglobulin receptors of target epithelial cells. Within these methods, expression of polymeric immunoglobulin receptors can be enhanced by cytokines.

Within more detailed aspects of the disclosure, antibodies and other immunological transport
20 agents can be themselves modified for enhanced delivery of γ PGA conjugates or other biologically active agents. For example, antibodies can be more effectively administered within the methods and compositions of the disclosure by charge modifying techniques. In one such aspect, an antibody drug delivery strategy involving antibody cationization is utilized that facilitates both trans-endothelial migration and target cell endocytosis (see, for example, Pardridge, *et al.*, *JPET* 286:548-44, 1998). In
25 one such strategy, the pI of the antibody is increased by converting surface carboxyl groups of the protein to extended primary amino groups. These cationized homologous proteins have no measurable tissue toxicity and have minimal immunogenicity. In addition, monoclonal antibodies can be cationized with retention of affinity for the target protein.

Additional selective transport-enhancing agents for use within the disclosure include whole
30 bacteria and viruses, including genetically engineered bacteria and viruses, as well as components of such bacteria and viruses. This aspect of the disclosure includes the use of bacterial ghosts and subunit constructs, for example, as described by Huter *et al.*, *J. Control. Rel.* 61:51-63, 1999. Bacterial ghosts are non-denatured bacterial cell envelopes, for example as produced by the controlled expression of the plasmid-encoded lysis gene E of bacteriophage PhiX174 in gram-negative bacteria. Protein E-specific
35 lysis does not cause any physical or chemical denaturation to bacterial surface structures, and bacterial ghosts are therefore useful in development of inactivated whole-cell vaccines. Ghosts produced from *Actinobacillus pleuropneumoniae*, *Pasteurella haemolytica* and *Salmonella sp.* have proved successful in vaccination experiments. Recombinant bacterial ghosts can be created by the expression of foreign

genes fused to a membrane-targeting sequence, and thus can carry foreign therapeutic peptides and proteins anchored in their envelope. The fact that bacterial ghosts preserve a native cell wall, including bioadhesive structures like fimbriae of their living counterparts, makes them suitable for the attachment to specific target tissues such as mucosal surfaces. Bacterial ghosts have been shown to be readily
5 taken up by macrophages, thus adhesion of ghosts to specific tissues can be followed by uptake through phagocytes.

In view of the foregoing, a wide variety of ligands involved in receptor-mediated transport mechanisms are known in the art and can be variously employed within the methods and compositions of the disclosure (for example, as conjugate partners or coordinately administered delivery enhancers)
10 to enhance delivery or receptor-mediated transport of γ PGA conjugates and other biologically active agents, including PA or other bacterial products. Generally, these ligands include hormones and growth factors, bacterial adhesins and toxins, lectins, metal ions and their carriers, vitamins, immunoglobulins, whole viruses and bacteria or selected components thereof. Exemplary ligands among these classes include, for example, calcitonin, prolactin, epidermal growth factor, glucagon, growth hormone,
15 estrogen, lutenizing hormone, platelet derived growth factor, thyroid stimulating hormone, thyroid hormone, cholera toxin, diphtheria toxin, *E. coli* heat labile toxin, Staphylococcal enterotoxins A and B, ricin, saporin, modeccin, nigrin, sarcin, concanavalin A, transcobalantin, catecholamines, transferrin, folate, riboflavin, vitamin B1, low density lipoprotein, maternal IgO, polymeric IgA, adenovirus, vesicular stomatitis virus, Rous sarcoma virus, *V. cholerae*, *Klebsiella* strains, *Serratia* strains,
20 parainfluenza virus, respiratory syncytial virus, Varicella zoster, and *Enterobacter* strains (see, for example, Swann, *Pharmaceutical Research* 15:826-32, 1998).

In certain additional embodiments of the disclosure, membrane-permeable peptides (for example, "arginine rich peptides") are employed to facilitate delivery of γ PGA conjugates or other biologically active agents of the disclosure. While the mechanism of action of these peptides remains
25 to be fully elucidated, they provide useful delivery enhancing adjuncts for use within the compositions and methods herein. In one example, a basic peptide derived from human immunodeficiency virus (HIV)-1 Tat protein (for example, residues 48-60) facilitates translocation through cell membranes and can be utilized for enhancing delivery of exogenous proteins and peptides into cells. The sequence of Tat (GRKKRRQRRPPQ, SEQ ID NO: 1) includes a highly
30 basic and hydrophilic peptide, which contains 6 arginine and 2 lysine residues in its 13 amino acid residues. Various other arginine-rich peptides have been identified which have a translocation activity similar to Tat-(48-60). These include such peptides as the D-amino acid- and arginine-substituted Tat-(48-60), the RNA-binding peptides derived from virus proteins, such as HIV-1 Rev, and flock house virus coat proteins, and the DNA binding segments of leucine zipper proteins, such
35 as cancer-related proteins c-Fos and c-Jun, and the yeast transcription factor GCN4 (see, for example, Futaki *et al.*, *J. Biol. Chem.* 276:5836-40, 2000).

While this disclosure has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and it is intended that the disclosure may be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications encompassed within the
5 spirit and scope of the disclosure as defined by the claims below.

CLAIMS

We claim:

- 5 1. An immunogenic conjugate comprising a *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide covalently linked to a carrier, wherein the conjugate elicits an immune response in a subject.
- 10 2. The conjugate of claim 1, wherein the conjugate comprises a γ PGA polypeptide comprising 1-20 glutamic acid residues.
3. The conjugate of claim 1, wherein the conjugate comprises a γ PGA polypeptide comprising 10-15 glutamic acid residues.
- 15 4. The conjugate of claim 1, wherein the conjugate comprises a decameric γ PGA polypeptide.
5. The conjugate of claim 1, wherein the carrier is selected from the group consisting of: (a) bovine serum albumin, (b) recombinant *B. anthracis* protective antigen, (c)
20 recombinant *P. aeruginosa* exotoxin A, (d) tetanus toxoid, (e) diphtheria toxoid, (f) pertussis toxoid, (g) *C. perfringens* toxoid, (h) hepatitis B surface antigen, (i) hepatitis B core antigen, (j) keyhole limpet hemocyanin, (k) horseshoe crab hemocyanin, (l) edestin, (m) mammalian serum albumins, (n) mammalian immunoglobulins, analogs or mimetics of (a)-
25 (n), and combinations of two or more thereof.
6. The conjugate of claim 1, wherein the carrier comprises recombinant *B. anthracis* protective antigen.
7. The conjugate of claim 1, wherein the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide comprises a *B. anthracis*, *B. licheniformis*, *B. pumilus*, or *B. subtilis*
30 γ PGA polypeptide.
8. The conjugate of claim 1, wherein the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide comprises the D- or L-conformation.
- 35 9. The conjugate of claim 1, wherein the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide comprises a *B. anthracis* γ DPGA polypeptide.

10. The conjugate of claim 1, wherein the *Bacillus* poly- γ -glutamic acid (γ PGA) polypeptide comprises a decameric *B. anthracis* γ DPGA polypeptide and the carrier comprises recombinant *B. anthracis* protective antigen.
- 5 11. The conjugate of claim 1, wherein the carrier is covalently linked to either the amino or carboxyl terminus of the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide.
- 10 12. The conjugate of claim 1, wherein the carrier is covalently linked to the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide via a thioether, disulfide, or amide bond.
13. The conjugate of claim 1, wherein the density of *Bacillus* poly- γ -glutamic acid (γ PGA) polypeptide to carrier is between about 5:1 and about 32:1.
- 15 14. The conjugate of claim 1, wherein the density of *Bacillus* poly- γ -glutamic acid (γ PGA) polypeptide to carrier is between about 10:1 and about 15:1.
- 20 15. The conjugate of claim 1, wherein the γ PGA polypeptide is covalently linked to the carrier via an aldehyde (CHO)/adipic acid hydrazide (AH) linkage.
16. A composition comprising the conjugate of any one of claims 1-15 and a pharmaceutically acceptable carrier.
- 25 17. The composition of claim 16, further comprising an adjuvant.
18. A composition comprising the conjugate of claim 9 and a pharmaceutically acceptable carrier.
- 30 19. The composition of claim 18, further comprising an adjuvant.
20. A method of eliciting an immune response against a *Bacillus* antigenic epitope in a subject, comprising introducing into the subject the composition of claim 17, thereby eliciting an immune response in the subject.
- 35 21. The method of claim 20, wherein the immune response is elicited against the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide.

22. The method of claim 20, wherein the immune response is elicited against the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide and the carrier protein.
23. The method of claim 20, wherein the immune response comprises opsonophagocytic activity.
24. A method of eliciting an immune response against a *B. anthracis* antigenic epitope in a subject, comprising introducing into the subject the composition of claim 19, thereby eliciting an immune response in the subject.
25. The method of claim 24, wherein the immune response is elicited against the *B. anthracis* capsular poly- γ -D-glutamic acid (γ DPGA) polypeptide.
26. The method of claim 24, wherein the immune response is elicited against the *B. anthracis* capsular poly- γ -D-glutamic acid (γ DPGA) polypeptide and the carrier protein.
27. The method of claim 24, wherein the immune response comprises opsonophagocytic activity.
28. An isolated antibody that binds to the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide of claim 1.
29. An isolated antibody that recognizes antigenic epitopes on both the *Bacillus* capsular poly- γ -glutamic acid (γ PGA) polypeptide and the carrier protein of claim 1.
30. An isolated antibody that binds to the *B. anthracis* capsular poly- γ -D-glutamic acid (γ DPGA) polypeptide of claim 9.
31. An isolated antibody that recognizes antigenic epitopes on both the *B. anthracis* capsular poly- γ -D-glutamic acid (γ DPGA) polypeptide and the carrier protein of claim 9.
32. A composition comprising the conjugate of any one of claims 1-15 for use in eliciting an immune response against a *Bacillus* antigenic epitope in a subject.
33. A composition comprising the conjugate of claim 9 for use in eliciting an immune response against a *B. anthracis* antigenic epitope in a subject.

1/2




FIG. 1

2/2




FIG. 2A-D

SEQUENCE LISTING

<110> THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS
 REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND
 HUMAN SERVICES
 Schneerson, Rachel
 Leppla, Stephen H.
 Robbins, John B.
 Shiloach, Joseph
 Kubler-Kielb, Joanna
 Liu, Darrell
 Majadly, Fathy

<120> GAMMA PGA CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED
 AGAINST BACILLI

<130> 4239-68226-01

<150> US 60/476,598
 <151> 2003-06-05

<160> 3

<170> PatentIn version 3.2

<210> 1
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Basic peptide derived from HIV-1 Tat protein.

<400> 1

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
 1 5 10

<210> 2
 <211> 2295
 <212> DNA
 <213> Bacillus anthracis

<220>
 <221> CDS
 <222> (1)..(2292)

<400> 2

atg aaa aaa cga aaa gtg tta ata cca tta atg gca ttg tct acg ata 48
 Met Lys Lys Arg Lys Val Leu Ile Pro Leu Met Ala Leu Ser Thr Ile
 1 5 10 15

tta gtt tca agc aca ggt aat tta gag gtg att cag gca gaa gtt aaa 96
 Leu Val Ser Ser Thr Gly Asn Leu Glu Val Ile Gln Ala Glu Val Lys
 20 25 30

cag gag aac cgg tta tta aat gaa tca gaa tca agt tcc cag ggg tta 144
 Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser Gln Gly Leu

35	40	45	
cta gga tac tat ttt agt gat ttg aat ttt caa gca ccc atg gtg gtt Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro Met Val Val 50 55 60			192
acc tct tct act aca ggg gat tta tct att cgt agt tct gag tta gaa Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser Glu Leu Glu 65 70 75 80			240
aat att cca tgc gaa aac caa tat ttt caa tct gct att tgg tca gga Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile Trp Ser Gly 85 90 95			288
ttt atc aaa gtt aag aag agt gat gaa tat aca ttt gct act tcc gct Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala Thr Ser Ala 100 105 110			336
gat aat cat gta aca atg tgg gta gat gac caa gaa gtg att aat aaa Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val Ile Asn Lys 115 120 125			384
gct tct aat tct aac aaa atc aga tta gaa aaa gga aga tta tat caa Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg Leu Tyr Gln 130 135 140			432
ata aaa att caa tat caa cga gaa aat cct act gaa aaa gga ttg gat Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys Gly Leu Asp 145 150 155 160			480
ttc aag ttg tac tgg acc gat tct caa aat aaa aaa gaa gtg att tct Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu Val Ile Ser 165 170 175			528
agt gat aac tta caa ttg cca gaa tta aaa caa aaa tct tgc aac tca Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser Ser Asn Ser 180 185 190			576
aga aaa aag cga agt aca agt gct gga cct acg gtt cca gac cgt gac Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp 195 200 205			624
aat gat gga atc cct gat tca tta gag gta gaa gga tat acg gtt gat Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp 210 215 220			672
gtc aaa aat aaa aga act ttt ctt tca cca tgg att tct aat att cat Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His 225 230 235 240			720
gaa aag aaa gga tta acc aaa tat aaa tca tct cct gaa aaa tgg agc Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser 245 250 255			768
acg gct tct gat ccg tac agt gat ttc gaa aag gtt aca gga cgg att Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile 260 265 270			816
gat aag aat gta tca cca gag gca aga cac ccc ctt gtg gca gct tat Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr			864

275	280	285	
ccg att gta cat gta gat atg gag aat att att ctc tca aaa aat gag Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu 290 295 300			912
gat caa tcc aca cag aat act gat agt caa acg aga aca ata agt aaa Asp Gln Ser Thr Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys 305 310 315 320			960
aat act tct aca agt agg aca cat act agt gaa gta cat gga aat gca Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala 325 330 335			1008
gaa gtg cat gcg tcg ttc ttt gat att ggt ggg agt gta tct gca gga Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly 340 345 350			1056
ttt agt aat tcg aat tca agt acg gtc gca att gat cat tca cta tct Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser 355 360 365			1104
cta gca ggg gaa aga act tgg gct gaa aca atg ggt tta aat acc gct Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala 370 375 380			1152
gat aca gca aga tta aat gcc aat att aga tat gta aat act ggg acg Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr 385 390 395 400			1200
gct cca atc tac aac gtg tta cca acg act tcg tta gtg tta gga aaa Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys 405 410 415			1248
aat caa aca ctc gcg aca att aaa gct aag gaa aac caa tta agt caa Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln 420 425 430			1296
ata ctt gca cct aat aat tat tat cct tct aaa aac ttg gcg cca atc Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile 435 440 445			1344
gca tta aat gca caa gac gat ttc agt tct act cca att aca atg aat Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn 450 455 460			1392
tac aat caa ttt ctt gag tta gaa aaa acg aaa caa tta aga tta gat Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp 465 470 475 480			1440
acg gat caa gta tat ggg aat ata gca aca tac aat ttt gaa aat gga Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly 485 490 495			1488
aga gtg agg gtg gat aca ggc tcg aac tgg agt gaa gtg tta ccg caa Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln 500 505 510			1536
att caa gaa aca act gca cgt atc att ttt aat gga aaa gat tta aat Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn			1584

515	520	525	
ctg gta gaa agg cgg ata gcg gcg gtt aat cct agt gat cca tta gaa Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu 530 535 540			1632
acg act aaa ccg gat atg aca tta aaa gaa gcc ctt aaa ata gca ttt Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe 545 550 555 560			1680
gga ttt aac gaa ccg aat gga aac tta caa tat caa ggg aaa gac ata Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile 565 570 575			1728
acc gaa ttt gat ttt aat ttc gat caa caa aca tct caa aat atc aag Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys 580 585 590			1776
aat cag tta gcg gaa tta aac gca act aac ata tat act gta tta gat Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp 595 600 605			1824
aaa atc aaa tta aat gca aaa atg aat att tta ata aga gat aaa cgt Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg 610 615 620			1872
ttt cat tat gat aga aat aac ata gca gtt ggg gcg gat gag tca gta Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val 625 630 635 640			1920
gtt aag gag gct cat aga gaa gta att aat tcg tca aca gag gga tta Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu 645 650 655			1968
ttg tta aat att gat aag gat ata aga aaa ata tta tca ggt tat att Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile 660 665 670			2016
gta gaa att gaa gat act gaa ggg ctt aaa gaa gtt ata aat gac aga Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg 675 680 685			2064
tat gat atg ttg aat att tct agt tta cgg caa gat gga aaa aca ttt Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe 690 695 700			2112
ata gat ttt aaa aaa tat aat gat aaa tta ccg tta tat ata agt aat Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn 705 710 715 720			2160
ccc aat tat aag gta aat gta tat gct gtt act aaa gaa aac act att Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile 725 730 735			2208
att aat cct agt gag aat ggg gat act agt acc aac ggg atc aag aaa Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys 740 745 750			2256
att tta atc ttt tct aaa aaa ggc tat gag ata gga taa Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly			2295

755

760

<210> 3
 <211> 764
 <212> PRT
 <213> Bacillus anthracis

<400> 3

Met Lys Lys Arg Lys Val Leu Ile Pro Leu Met Ala Leu Ser Thr Ile
 1 5 10 15

Leu Val Ser Ser Thr Gly Asn Leu Glu Val Ile Gln Ala Glu Val Lys
 20 25 30

Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser Gln Gly Leu
 35 40 45

Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro Met Val Val
 50 55 60

Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser Glu Leu Glu
 65 70 75 80

Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile Trp Ser Gly
 85 90 95

Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala Thr Ser Ala
 100 105 110

Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val Ile Asn Lys
 115 120 125

Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg Leu Tyr Gln
 130 135 140

Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys Gly Leu Asp
 145 150 155 160

Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu Val Ile Ser
 165 170 175

Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser Ser Asn Ser
 180 185 190

Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp
 195 200 205

Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp
 210 215 220

Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His
 225 230 235 240

Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser
 245 250 255

Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile
 260 265 270

Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr
 275 280 285

Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu
 290 295 300

Asp Gln Ser Thr Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys
 305 310 315 320

Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala
 325 330 335

Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly
 340 345 350

Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser
 355 360 365

Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala
 370 375 380

Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr
 385 390 395 400

Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys
 405 410 415

Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln
 420 425 430

Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile
 435 440 445

Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn
 450 455 460

Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp
 465 470 475 480

Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly
 485 490 495

Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln
 500 505 510

Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn
 515 520 525

Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu
 530 535 540

Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe
 545 550 555 560

Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile
 565 570 575

Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys
 580 585 590

Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp
 595 600 605

Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg
 610 615 620

Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val
 625 630 635 640

Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu
 645 650 655

Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile
 660 665 670

Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg
 675 680 685

Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe
690 695 700

Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn
705 710 715 720

Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile
725 730 735

Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys
740 745 750

Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
755 760

THIS PAGE LEFT BLANK

INTERNATIONAL SEARCH REPORT

Internal application No
PCT/US2004/017736

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/32 A61K39/07 A61P31/04 C07K16/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALKAN, SEFIK S. ET AL: "Antigen recognition and the immune response. Capacity of L-tyrosine-azobenzene arsonate to serve as a carrier for a macromolecular hapten" JOURNAL OF IMMUNOLOGY, 107(2), 353-8 CODEN: JOIMA3; ISSN: 0022-1767, 1971, XP009039727	1-5, 7-9, 11-33
Y	abstract; page 354, right-hand column, second paragraph; paragraph joining pages 355 and 356; page 356, paragraph joining left- and right-hand column; page 357, left-hand column, first paragraph ----- -/--	6, 10

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

18 November 2004

Date of mailing of the international search report

08/12/2004

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Faustl, S

INTERNATIONAL SEARCH REPORT

Intern: application No
PCT/US2004/017736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>GOODMAN J W ET AL: "Immunochemical studies on the poly-gamma-D-glutamyl capsule of Bacillus anthracis. 3. The activity with rabbit antisera of peptides derived from the homologous polypeptide." BIOCHEMISTRY. FEB 1968, vol. 7, no. 2, February 1968 (1968-02), pages 706-710, XP001203672 ISSN: 0006-2960 abstract; page 706; right-hand column, lines 10-13</p> <p>-----</p>	28-31
X	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1975 (1975-02), KLAUS G G ET AL: "The immunological properties of haptens coupled to thymus-independent carrier molecules. III. The role of the immunogenicity and mitogenicity of the carrier in the induction of primary IgM anti-hapten responses." XP002306078 Database accession no. NLM10166 abstract & EUROPEAN JOURNAL OF IMMUNOLOGY. FEB 1975, vol. 5, no. 2, February 1975 (1975-02), pages 105-111, ISSN: 0014-2980</p> <p>-----</p>	1-4,7-9, 11-19, 32,33
X	<p>SENYK, GEORGE ET AL: "Immune response to glucagon in conjugated form" IMMUNOCHEMISTRY, 9(2), 97-110 CODEN: IMCHAZ; ISSN: 0019-2791, 1972, XP009039720 abstract; paragraph joining pages 98 and 99</p> <p>-----</p>	1-4,7-9, 11-19, 32,33
X	<p>F PRODHOMME EMMANUEL J -P ET AL: "Poly-gamma-D-glutamic acid as a template for functionalized water-soluble biomaterials" ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 219, no. 1-2, 2000, page BIOL 133, XP009039728 & 219TH MEETING OF THE AMERICAN CHEMICAL SOCIETY.; SAN FRANCISCO, CALIFORNIA, USA; MARCH 26-30, 2000 ISSN: 0065-7727 abstract</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-4,7,8, 11-17

INTERNATIONAL SEARCH REPORT

Intern

Application No

PCT/US2004/017736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>SCHNEERSON RACHEL ET AL: "Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: A potential addition to the anthrax vaccine." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 15, 22 July 2003 (2003-07-22), pages 8945-8950, XP002306072 ISSN: 0027-8424 the whole document</p>	1-33
Y	<p>LEPPLA STEPHEN H ET AL: "Development of an improved vaccine for anthrax" JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 2, July 2002 (2002-07), pages 141-144, XP002306073 ISSN: 0021-9738 page 143, left-hand column, line 1 - right-hand column, line 11</p>	6,10
A	<p>WELKOS SUSAN ET AL: "The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores" MICROBIOLOGY (READING), vol. 147, no. 6, June 2001 (2001-06), pages 1677-1685, XP002306074 ISSN: 1350-0872 abstract; page 1678, left-hand column, lines 7-14; paragraph joining pages 1682 and 1683; page 1684; paragraph joining left- and right-hand columns</p>	1-33
A	<p>WO 01/60412 A (GENZYME CORP) 23 August 2001 (2001-08-23) paragraph joining pages 6 and 7; claims 1 and 7</p>	12-14

INTERNATIONAL SEARCH REPORT

Int application No.
PCT/US2004/017736

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 20-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internationa l publication No
PCT/US2004/017736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0160412 A	23-08-2001	AU 3834601 A	27-08-2001
		CA 2400205 A1	23-08-2001
		EP 1263472 A2	11-12-2002
		JP 2003522806 T	29-07-2003
		WO 0160412 A2	23-08-2001
		US 2003087877 A1	08-05-2003
		US 2004209842 A1	21-10-2004
<hr/>			

THIS PAGE LEFT BLANK